ClinicalTrials.gg
CompletedNCT01175213Updated May 19, 2021Results posted

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

A Phase 3 interventional study of SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) and SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 11 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
3rd of 18
66 · median 47
Started
2010
the only one that year
Phase 3
9 of 23
none open now
Registered
6th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2010, is one of 9 in phase 3, and was the 6th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

The original purpose of the study is to assess the long-term safety, tolerability, and practicability of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous Solution (IGSC), 10% facilitated with recombinant human hyaluronidase (rHuPH20) in participants with Primary Immunodeficiency Diseases (PID) who have completed Baxter Clinical Study Protocol No. 160603.

Following a discussion with the FDA, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up.

During this safety follow-up period, participants underwent either intravenous (IV) or SC treatment with IGSC, 10%. The IV or SC administration route was at the discretion of the participant and the investigator.

Read the detailed description

IGSC, 10% is the same product as IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% (IGIV, 10%) quoted in study 160603.

IGSC, 10% is abbreviated to IGI, 10% [IMMUNE GLOBULIN INFUSION (HUMAN), 10%]

In the US the product is licensed (trade name GAMMAGARD LIQUID) for the intravenous (IV) and SC replacement therapy of antibody deficiency in patients with PID.

In the EU this product is licensed (trade name KIOVIG)

IGSC, 10% with rHuPH20 established name is Innume Glubulin Infusion 10% (Human) with Recombinant Human Hyualuronidase.

US trade name is HYQVIA EU trade name is HyQvia

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has completed or is about to complete Baxter Clinical Study Protocol No. 160603. Participants who have discontinued rHuPH20 and reverted to intravenous or subcutaneous treatment due to an anti-rHuPH20 antibody also may enroll for long-term safety monitoring.
  • Participant/caretaker has reviewed, signed and dated
  • Participant is willing and able to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in Study 160902
  • Participant is scheduled to participate in another non-Baxter clinical study involving an product or investigational device during the course of this study
  • If female of , participant is pregnant or has a negative pregnancy test and does not agree to employ adequate measures for the duration of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)

    Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)

    Biological: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)

  • Experimental
    SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety

    Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)

    Biological: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)

  • Experimental
    IV treatment with IGSC, 10% only

    Partial efficacy (trough levels of immunoglobulin G \[IgG\] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603

    Biological: IV treatment with IGSC, 10%

Interventions

  • BiologicalSC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)

    Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320). After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator. During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37.

    Also known as: HYQVIA (IGSC, 10% with rHuPH20 [US]), 10% with rHuPH20 [EU]), GAMMAGARD LIQUID (IGSC, 10% [US]), KIOVIG (IGSC, 10% [EU])

  • BiologicalSC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)

    Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320). After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator. During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose.

    Also known as: GAMMAGARD LIQUID (IGSC, 10% [US]), KIOVIG (IGSC, 10% [EU]), HyQvia (IGSC, 10% with rHuPH20 [EU]), 10% with rHuPH20 [US])

  • BiologicalIV treatment with IGSC, 10%

    During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.

    Also known as: GAMMAGARD LIQUID (US), KIOVIG (EU)

06

What researchers measure

Primary outcomes

  1. Annual Rate of Serious Bacterial Infections

    The point estimate of the annual rate of validated acute serious bacterial infections (VASBIs) per participant per year was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.

    Time frame: Throughout the efficacy period only (from 60 to 729 days)

  2. Annual Rate of All Infections

    Annualized rate of infections per participant as defined by MedDRA system organ class (SOC) "infections and infestations". The point estimate of the annual rate of all infections was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.

    Time frame: Throughout the efficacy period only (from 60 to 729 days)

  3. Trough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency

    Immunoglobulin (IgG) steady state trough levels were measured in relation to dose frequency by measuring in relation to treatment interval (2-, 3- or 4-week intervals). Initially participants were administered subcutaneous (SC) infusions of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20) \[or IV infusions of IGSC, 10% only\] at the treatment intervals and dose determined by epoch 2 of study 160603 (3- or 4-week intervals). After 3 treatment intervals (either 3- or 4- week intervals), participants changed to a 2-week treatment interval, if agreed with participant and investigator, with the dose adjusted to 1/2 of the 4-week dose or 2/3 of the 3-week dose, whichever was applicable. The rHuPH20 dose was adjusted relative to the new IGSC, 10% dose in order to achieve a dose ratio of 75 U/g IgG. This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.

    Time frame: Throughout the efficacy period only (from 60 to 729 days)

Secondary outcomes

  1. The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs

    Separated into age groups as described below and into related (related to either study drug) and not related (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution (IGSC), 10% and recombinant human hyaluronidase (rHuPH20).

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  2. Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for AEs

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  3. Percentage of Infusions Associated With One or More Moderate or Severe AEs (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of an Infusion

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  4. Number of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20

    Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.

    Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)

  5. Percentage of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20

    Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.

    Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)

  6. Number of Participants With AEs Related to Anti-rHuPH20 Titers

    Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)

  7. Percentage of Participants With AEs Related to Anti-rHuPH20 Titers

    Time frame: Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)

  8. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (A-F).

    Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: CPK - Creatinine Phosphokinase Inc. - Increased Dis - Disease Sml- small

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  9. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (G-M).

    Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  10. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (N-Z).

    Categories presented as Preferred Term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Infection - Inf.

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  11. Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).

    Categories presented as Preferred Term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  12. Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).

    Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  13. Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).

    Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  14. Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).

    Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious adverse event; SAE- serious adverse event Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  15. Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).

    Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  16. Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).

    Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  17. Rate of AEs Per Participant (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")

    Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  18. Rate of AEs Per Infusion (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")

    Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  19. Rate of AEs Per Participant (Including and Excluding Infections) Temporarily Associated With the Infusion

    Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (nsAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  20. Rate of AEs Per Infusion (Including and Excluding Infections) Temporarily Associated With the Infusion

    Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (non-SAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

  21. Percentage of Infusions Associated With One or More Local AEs (Including and Excluding Infections), at Any Time During the Study

    Time frame: Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.

07

Results

Posted May 26, 2016

Participant flow

Recruitment was conducted 11 clinical sites in the United States.

IGSC, 10%/rHuPH20
Participant flow — IGSC, 10%/rHuPH20
MilestoneIGSC - rHuPH20 Then IGSC, 10% or IGIV, 10% OnlyIGIV, 10% Only
Started633
Completed483
Not completed150
Withdrew: Withdrawal by subject40
Withdrew: Death10
Withdrew: Bone marrow transplant10
Withdrew: Clinical site closed by sponsor60
Withdrew: Site elected to exit study30
Safety Follow-up
Participant flow — Safety Follow-up
MilestoneIGSC - rHuPH20 Then IGSC, 10% or IGIV, 10% OnlyIGIV, 10% Only
Started483
Completed473
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryAnnual Rate of Serious Bacterial Infections

The point estimate of the annual rate of validated acute serious bacterial infections (VASBIs) per participant per year was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.

Time frame:
Throughout the efficacy period only (from 60 to 729 days)
Reported as:
Number · Estimated infections/year
Annual Rate of Serious Bacterial Infections
Estimated infections/yearAll Participants Treated With IGSC, 10% and rHuPH20
Annual Rate of Serious Bacterial Infections0.020
Statistical analysis
  • All Participants Treated With IGSC, 10% and rHuPH20 · Poisson · p = <0.0001 (Testing the null hypothesis of 1 VASBI/year against a one-sided alternative at the 0.01 level of statistical significance.) · Poisson: 0.020
PrimaryAnnual Rate of All Infections

Annualized rate of infections per participant as defined by MedDRA system organ class (SOC) "infections and infestations". The point estimate of the annual rate of all infections was provided during subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20). This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.

Time frame:
Throughout the efficacy period only (from 60 to 729 days)
Reported as:
Number · Number of infections/year
Annual Rate of All Infections
Number of infections/yearAll Participants Treated With IGSC, 10% and rHuPH20
Annual Rate of All Infections2.86 (2.36 to 3.43)
PrimaryTrough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency

Immunoglobulin (IgG) steady state trough levels were measured in relation to dose frequency by measuring in relation to treatment interval (2-, 3- or 4-week intervals). Initially participants were administered subcutaneous (SC) infusions of Immune Globulin Subcutaneous Solution (IGSC), 10%, after SC administration of human recombinant hyaluronidase (rHuPH20) \[or IV infusions of IGSC, 10% only\] at the treatment intervals and dose determined by epoch 2 of study 160603 (3- or 4-week intervals). After 3 treatment intervals (either 3- or 4- week intervals), participants changed to a 2-week treatment interval, if agreed with participant and investigator, with the dose adjusted to 1/2 of the 4-week dose or 2/3 of the 3-week dose, whichever was applicable. The rHuPH20 dose was adjusted relative to the new IGSC, 10% dose in order to achieve a dose ratio of 75 U/g IgG. This efficacy outcome measure was only applicable prior to the safety follow-up i.e. before discontinuation of rHuPH20.

Time frame:
Throughout the efficacy period only (from 60 to 729 days)
Reported as:
Median · g/L
Trough Levels of IgG Maintained During the Study Period in Relation to Dose Frequency
g/LAll Participants Treated With rHuPH20 and/or IGSC, 10%
2-Week Treatment Interval [N=17]10.900 (9.390 to 13.300)
3-Week Treatment Interval [N=9]12.300 (11.500 to 15.300)
4-Week Treatment Interval [N=47]9.760 (9.260 to 10.700)
SecondaryThe Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs

Separated into age groups as described below and into related (related to either study drug) and not related (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution (IGSC), 10% and recombinant human hyaluronidase (rHuPH20).

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · SAEs/year
The Annual Rate of Serious Adverse Events (SAEs), Related and Not Related to Study Drugs
SAEs/yearIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Participants aged 2 to <12 years - not related0.00000.0000
Participants aged 2 to <12 years - related0.00000.0000
Participants aged 12 to <16 years - not related0.07680.0000
Participants aged 12 to <16 years - related0.00000.0000
Participants aged 16 to <65 years - not related0.09500.0449
Participants aged 16 to <65 years - related0.00000.0000
Participants aged 65 years and older- not related0.57370.4728
Participants aged 65 years and older- related0.00000.0000
SecondaryPercentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for AEs
Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Percentage of infusions
Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for AEs
Percentage of infusionsIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Percentage of infusion rates reduced1.30.3
Percentage of infusions interrupted0.80.2
Percentage of infusions stopped0.10.2
SecondaryPercentage of Infusions Associated With One or More Moderate or Severe AEs (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of an Infusion
Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With One or More Moderate or Severe AEs (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of an Infusion
Percentage of infusionsIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Including Infections3.44.7
Excluding Infections2.94.0
SecondaryNumber of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20

Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.

Time frame:
Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Reported as:
Number · Number of participants
Number of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20
Number of participantsAll Participants Treated With rHuPH20
Binding antibodies (>=1:160)13
Neutralizing antibodies0
SecondaryPercentage of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20

Participants who develop binding antibodies and/or neutralizing antibodies to recombinant human hyaluronidase (rHuPH20) from study 160603 and/ or from this study (160902) are included here. This study (160902) is an extension of study 160603. Study 160603 was divided into 2 study epochs. In epoch 1 of study 160603 participants were treated with intravenous (IV) administration of Immune Globulin Subcutaneous Solution (IGSC), 10%. In epoch 2 of study 160603 participants were treated with subcutaneous (SC) administration of IGSC, 10% after SC administration of rHuPH20. Only participants who completed study 160603 were eligible to be screened and enrolled in this study (160902). In this study, participants started on same doses of IGSC, 10% and rHuPH20 that were used for the last infusions in epoch 2 of study 160603.

Time frame:
Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Develop Antibodies and Neutralizing Antibodies to rHuPH20
Percentage of participantsAll Participants Treated With rHuPH20
Binding antibodies (>=1:160)19.7
Neutralizing antibodies0
SecondaryNumber of Participants With AEs Related to Anti-rHuPH20 Titers
Time frame:
Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Reported as:
Number · Number of participants
Number of Participants With AEs Related to Anti-rHuPH20 Titers
Number of participantsAll Participants Treated With rHuPH20
Number of Participants With AEs Related to Anti-rHuPH20 Titers12
SecondaryPercentage of Participants With AEs Related to Anti-rHuPH20 Titers
Time frame:
Throughout entire study period for 160603 (1 year 11 months) and 160902 (2 years 11 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Related to Anti-rHuPH20 Titers
Percentage of participantsAll Participants Treated With rHuPH20
Percentage of Participants With AEs Related to Anti-rHuPH20 Titers92.3
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (A-F).

Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: CPK - Creatinine Phosphokinase Inc. - Increased Dis - Disease Sml- small

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (A-F).
Number of AEsIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Abdominal Distension-non-SAE-R-Mild60
Abdominal Hernia-non-SAE-NR-Mild10
Abdominal Mass-non-SAE-NR-Mild01
Abdominal Pain-non-SAE-NR-Mild21
Abdominal Pain-non-SAE-NR-Mod40
Abdominal Pain-non-SAE-NR-Severe10
Abdominal Pain-non-SAE-R-Mild03
Abdominal Pain Upper-non-SAE-NR-Mild70
Abdominal Pain Upper-non-SAE-R-Mild10
Abdominal Tenderness-non-SAE-NR-Mild20
Abdominal Tenderness-non-SAE-R-Mild10
Abnormal Loss Of Weight-non-SAE-NR-Mild10
Acarodermatitis-non-SAE-NR-Mild21
Acarodermatitis-non-SAE-NR-Mod20
Acne-non-SAE-NR-Mild10
Acne-non-SAE-NR-Mod10
Actinic Keratosis-non-SAE-NR-Mild10
Actinic Keratosis-non-SAE-NR-Mod12
Activities of Daily Living Impaired-non-SAE-NR-Mod10
Acute Sinusitis-non-SAE-NR-Mild01
Acute Sinusitis-non-SAE-NR-Mod10
Acute Stress Disorder-non-SAE-NR-Mild10
Adhesiolysis-SAE-NR-Mod10
Age Related Macular Degeneration-non-SAE-NR-Mild10
Agitation-non-SAE-NR-Mild10
Aldolase Increased-non-SAE-NR-Mild10
Anaphylactic Reaction-non-SAE-R-Sev01
Animal Bite-non-SAE-NR-Mild10
Animal Scratch-non-SAE-NR-Mild01
Anxiety-non-SAE-NR-Mild20
Anxiety-non-SAE-NR-Mod20
Aortic Calcification-non-SAE-NR-Mild10
Aortic Stenosis-non-SAE-NR-Mild10
Aortic Stenosis-non-SAE-NR-Mod10
Aortic Valve Incompetence-non-SAE-NR-Mod10
Aortic Valve Incompetence-SAE-NR-Sev10
Apthous Stomatitis-non-SAE-NR-Mild42
Apthous Stomatitis-non-SAE-NR-Mod20
Apthous Stomatitis-non-SAE-R-Mild10
Appendicitis-SAE-NR-Mod10
Application Site Erythema-non-SAE-NR-Mild10
Arteritis-non-SAE-NR-Mod10
Arthralgia-non-SAE-NR-Mild71
Arthralgia-non-SAE-NR-Mod06
Arthralgia-non-SAE-R-Mild10
Arthropod Bite-non-SAE-NR-Mild11
Asthenia-non-SAE-NR-Mild10
Asthenia-non-SAE-NR-Mod20
Asthenia-non-SAE-R-Mild60
Asthenia-non-SAE-R-Mod71
Asthma-non-SAE-NR-Mild123
Asthma-non-SAE-NR-Mod203
Ataxia-non-SAE-NR-Mild20
Atelectasis-non-SAE-NR-Mild10
Atrial Fibrillation-non-SAE-NR-Mild10
Atrial Fibrillation-SAE-NR-Mod10
ADHD-non-SAE-NR-Mod10
Back Pain-non-SAE-NR-Mild32
Back Pain-non-SAE-NR-Mod32
Back Pain-non-SAE-R-Sev01
Basal Cell Carcinoma-non-SAE-NR-Mild10
Basal Cell Carcinoma-non-SAE-NR-Mod41
Blepharochalasis-non-SAE-NR-Mild10
Blister-non-SAE-NR-Mild10
Blood Bicarbonate Decreased-non-SAE-NR-Mild10
Blood CPK Increased-non-SAE-NR-Mild30
Blood CPK Increased-non-SAE-NR-Mod20
Blood Creatinine Increased-non-SAE-NR-Mild10
Blood Creatinine Increased-non-SAE-R-Mild01
Blood Glucose Increased-non-SAE-NR-Mild41
Blood Urea Increased-non-SAE-R-Mild01
Blood Urine Present-non-SAE-NR-Mild20
Body Tinea-non-SAE-NR-Mild20
Bone Pain-non-SAE-NR-Mild10
Breast Calcifications-non-SAE-NR-Mild10
Breast Dysplasia-non-SAE-NR-Mild01
Bronchiolitis-non-SAE-NR-Mild10
Bronchitis-non-SAE-NR-Mild115
Bronchitis-non-SAE-NR-Mod112
Burns Second Degree-non-SAE-NR-Mild10
Bursitis-non-SAE-NR-Mild20
Candidiasis-non-SAE-NR-Mild10
Cardiac Failure Congestive-SAE-NR-Mild10
Cardiac Murmur-non-SAE-NR-Mod20
Cardiomegaly-non-SAE-NR-Mild01
Cardiomegaly-non-SAE-NR-Mod20
Cardiomyopathy-non-SAE-NR-Mild10
Cataract-non-SAE-NR-Mild11
Cataract-non-SAE-NR-Mod20
Cellulitis-non-SAE-NR-Mild20
Cellulitis-non-SAE-NR-Mod21
Cellulitis-SAE-NR-Mod01
Cellulitis Male Ext. Genital Organ-non-SAE-NR-Mod10
Cerebral Sml Vessel Ischaemic Dis-non-SAE-NR-Mild10
Cerumen Impaction-non-SAE-NR-Mild22
Cervical Spinal Stenosis-non-SAE-NR-Mild01
Chapped Lips-non-SAE-NR-Mild10
Cheilitis-non-SAE-NR-Mild10
Chest Discomfort-non-SAE-NR-Mild10
Chest Pain-non-SAE-NR-Mild20
Chest Pain-non-SAE-NR-Mod10
Chills-non-SAE-NR-Mild20
Chills-non-SAE-NR-Mod10
Chills-non-SAE-R-Mild111
Cholelithiasis-non-SAE-NR-Mild20
Chondromalacia-non-SAE-NR-Mod10
Chromaturia-non-SAE-NR-Mild10
COPD-non-SAE-NR-Mild20
COPD-non-SAE-NR-Mod30
COPD-SAE-NR-Mod10
COPD-SAE-NR-Sev10
Chronic Sinusitis-non-SAE-NR-Mild52
Chronic Sinusitis-non-SAE-NR-Mod31
Conjunctival Haemorrhage-non-SAE-NR-Mild10
Conjunctival Hyperaemia-non-SAE-NR-Mild20
Conjunctivitis-non-SAE-NR-Mild02
Conjunctivitis Allergic-non-SAE-NR-Mild11
Conjunctivitis Allergic-non-SAE-NR-Mod02
Conjunctivitis Infective-non-SAE-NR-Mild31
Constipation-non-SAE-NR-Mild33
Constipation-non-SAE-NR-Mod30
Contusion-non-SAE-NR-Mild03
Convulsion-non-SAE-NR-Mild10
Convulsion-non-SAE-NR-Mod21
Coombs Direct Test Positive-non-SAE-R-Mild10
Coombs Test Positive-non-SAE-NR-Mild10
Coombs Test Positive-non-SAE-R-Mild10
Corneal Abrasion-non-SAE-NR-Mild10
Costochondritis-non-SAE-NR-Mild10
Costochondritis-non-SAE-NR-Sev10
Cough-non-SAE-NR-Mild103
Cough-non-SAE-NR-Mod31
Cough-non-SAE-R-Mild10
Cryptosporidiosis Infection-SAE-NR-Sev10
Cyst-non-SAE-NR-Mild10
Cyst-non-SAE-NR-Mod20
Cystitis-non-SAE-NR-Mild10
Cystocele-SAE-NR-Mod10
Decreased Appetite-non-SAE-NR-Mild10
Decreased Appetite-non-SAE-NR-Mod20
Decreased Appetite-non-SAE-R-Mild38
Dehydration-non-SAE-NR-Mild10
Dehydration-non-SAE-NR-Mod10
Dental Caries-non-SAE-NR-Mod20
Depression-non-SAE-NR-Mild10
Depression-non-SAE-NR-Mod31
Dermal Cyst-non-SAE-NR-Mod10
Dermatitis-non-SAE-NR-Mild10
Dermatitis Allergic-non-SAE-NR-Mild01
Dermatitis Atopic-non-SAE-NR-Mild10
Dermatitis Contact-non-SAE-NR-Mild30
Dermatitis Contact-non-SAE-NR-Mod10
Dermatitis Psoriasiform-non-SAE-NR-Sev10
Device Breakage-non-SAE-NR-Mod10
Device Failure-non-SAE-NR-Mod10
Diarrhoea-non-SAE-NR-Mild154
Diarrhoea-non-SAE-NR-Mod20
Diarrhoea-non-SAE-R-Mild21
Dizziness-non-SAE-NR-Mild51
Dizziness-non-SAE-R-Mild50
Dizziness-non-SAE-R-Mod10
Drug Eruption-non-SAE-NR-Mod10
Drug Hypersensitivity-non-SAE-NR-Mild30
Dry Eye-non-SAE-NR-Mild10
Dry Eye-non-SAE-NR-Mod11
Dry Mouth-non-SAE-NR-Mild01
Dry Skin-non-SAE-NR-Mild01
Dysmenorrhoea-non-SAE-NR-Mild10
Dyspepsia-non-SAE-NR-Mild03
Dysplastic Naevus-non-SAE-NR-Mod10
Dyspnoea-non-SAE-NR-Mild21
Dyspnoea-non-SAE-NR-Mod20
Dysuria-non-SAE-NR-Mild11
Dysuria-non-SAE-NR-Mod20
Ear Infection-non-SAE-NR-Mild10
Ear Infection-non-SAE-NR-Mod30
Ear Pain-non-SAE-NR-Mild10
Ear Pain-non-SAE-NR-Mod20
Ear Pruritus-non-SAE-R-Mild01
Eccymosis-non-SAE-NR-Mild30
Eccymosis-non-SAE-NR-Mod01
Eczema-non-SAE-NR-Mild02
Eczema-non-SAE-NR-Mod50
Empty Sella Syndrome-non-SAE-NR-Mild10
Epilepsy-non-SAE-NR-Mod10
Epitaxis-non-SAE-NR-Mild115
Erythema-non-SAE-NR-Mild10
Eschar-non-SAE-NR-Mild10
Excoriation-non-SAE-NR-Mild81
Excoriation-non-SAE-NR-Mod10
Eye Haemorrhage-non-SAE-NR-Mild10
Eye Infection-non-SAE-NR-Mild11
Eye Pain-non-SAE-NR-Mild01
Eye Swelling-non-SAE-NR-Mild10
Eyelid Ptosis-non-SAE-NR-Mild10
Facial Bones Fracture-non-SAE-NR-Mod01
Facial Pain-non-SAE-NR-Mod10
Fall-non-SAE-NR-Mild31
Fall-non-SAE-NR-Sev01
Fatigue-non-SAE-NR-Mild71
Fatigue-non-SAE-NR-Mod31
Fatigue-non-SAE-NR-Severe10
Fatigue-non-SAE-R-Mild1314
Fatigue-non-SAE-R-Mod37
Femur Fracture-SAE-NR-Sev01
Fibromyalgia-non-SAE-NR-Mod21
Flatulence-non-SAE-NR-Mod10
Flushing-non-SAE-NR-Mod10
Folliculitis-non-SAE-NR-Mild10
Food Poisoning-non-SAE-NR-Mild20
Food Poisoning-non-SAE-NR-Mod10
Foot Fracture-non-SAE-NR-Mod10
Free Haemoglobin Present-non-SAE-NR-Mild10
Free Haemoglobin Present-non-SAE-NR-Mod10
Free Haemoglobin Present-non-SAE-R-Mild10
Free Haemoglobin Present-non-SAE-R-Mod10
Frequent Bowel Movements-non-SAE-NR-Mod10
Fungal Infection-non-SAE-NR-Mild11
Fungal Skin Infection-non-SAE-NR-Mild10
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (G-M).

Categories presented as Preferred Term-Seriousness-Relatedness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (G-M).
Number of AEsIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Gastric Stenosis-non-SAE-NR-Mod10
Gastritis-non-SAE-NR-Mild10
Gastroenteritis-non-SAE-NR-Mild30
Gastroenteritis-non-SAE-NR-Mod20
Gastroenteritis Salmonella-non-SAE-NR-Mod10
Gastroenteritis Viral-non-SAE-NR-Mild41
Gastroenteritis Viral-non-SAE-NR-Mod31
Gastrointestinal Viral Infection-non-SAE-NR-Mild10
Gastrooesophageal Reflux Disease-non-SAE-NR-Mild30
Gastrooesophageal Reflux Disease-non-SAE-NR-Mod10
Genital Herpes-non-SAE-NR-Mild22
Genital Herpes-non-SAE-NR-Mod01
Gingival Erosion-non-SAE-NR-Mild10
Gingivitis-non-SAE-NR-Mild10
Glaucoma-non-SAE-NR-Mod10
Glycosuria-non-SAE-NR-Mild10
Gout-non-SAE-NR-Mod10
Haematochezia-non-SAE-NR-Mild10
Haematospermia-non-SAE-NR-Mild10
Haematuria-non-SAE-NR-Mild11
Haemoglobin Decreased-non-SAE-R-Mild01
Haemolysis-non-SAE-R-Mild10
Haemorrhoids-non-SAE-NR-Mild20
Haemorrhoids-non-SAE-NR-Mod20
Hand Fracture-non-SAE-NR-Mod10
Headache-non-SAE-NR-Mild225
Headache-non-SAE-NR-Mod40
Headache-non-SAE-R-Mild1934
Headache-non-SAE-R-Mod22
Heart Rate Irregular-non-SAE-NR-Mild21
Herpes Zoster-non-SAE-NR-Mod30
Hiatus Hernia-non-SAE-NR-Mild10
Hydrocele-non-SAE-NR-Mild10
Hypercapnia-non-SAE-Mild10
Hypercholesterolaemia-non-SAE-NR-Mild10
Hypersensitivity-non-SAE-NR-Mild20
Hypertension-non-SAE-NR-Mild11
Hypertension-non-SAE-NR-Mod60
Hypertension-SAE-NR-Mod10
Hypoaesthesia-non-SAE-NR-Mild10
Hypokalaemia-non-SAE-NR-Mild02
Hypothyroidism-non-SAE-NR-Mild02
Hypothyroidism-non-SAE-NR-Mod10
Impetigo-non-SAE-NR-Mild20
Incision Site Pain-non-SAE-NR-Mod10
Increased Upper Airway Secretion-non-SAE-NR-Mild10
Inflammation Of Wound-non-SAE-NR-Mild01
Influenza-non-SAE-NR-Mod64
Influenza Like Illness-non-SAE-NR-Mild30
Influenza Like Illness-non-SAE-NR-Mod10
Infusion Site Abscess-non-SAE-R-Mild10
Infusion Site Bruising-non-SAE-R-Mild10
Infusion Site Discolouration-non-SAE-R-Mild10
Infusion Site Discomfort-non-SAE-R-Mild82
Infusion Site Erythema-non-SAE-R-Mild220
Infusion Site Erythema-non-SAE-R-Mod10
Infusion Site Induration-non-SAE-R-Mild20
Infusion Site Mass-non-SAE-R-Mild10
Infusion Site Oedema-non-SAE-R-Mild10
Infusion Site Pain-non-SAE-NR-Mod02
Infusion Site Pain-non-SAE-R-Mild7817
Infusion Site Pain-non-SAE-R-Mod60
Infusion Site Pruritus-non-SAE-R-Mild310
Infusion Site Swelling-non-SAE-R-Mild30
Infusion Site Swelling-non-SAE-R-Sev10
Injection Site Pain-non-SAE-NR-Mild10
Injection Site Pain-non-SAE-R-Mild20
Insomnia-non-SAE-NR-Mild50
Insomnia-non-SAE-NR-Mod01
Intervertebral Disc Degeneration-non-SAE-NR-Mild10
Iron Deficiency Anaemia-non-SAE-NR-Mild10
Irritable Bowel Syndrome-non-SAE-NR-Mod20
Jejunal Stenosis-non-SAE-NR-Mod10
Joint Dislocation-non-SAE-NR-Sev10
Joint Injury-non-SAE-NR-Mild20
Joint Swelling-non-SAE-NR-Mod01
Laceration-non-SAE-NR-Mild01
Ligament Sprain-non-SAE-NR-Mild20
Ligament Sprain-non-SAE-NR-Mod12
Limb Discomfort-non-SAE-NR-Mild01
Liver Function Test Abnormal-non-SAE-NR-Mild10
Local Swelling-non-SAE-NR-Mild10
Local Swelling-non-SAE-R-Mild20
Localised Infection-non-SAE-NR-Mod10
Loss Of Consciousness-non-SAE-NR-Mild01
Lyme Disease-non-SAE-NR-Mild20
Lymph Gland Infection-non-SAE-NR-Mod10
Lymphadenitis-non-SAE-NR-Mod01
Lymphadenitis Bacterial-non-SAE-NR-Mild20
Lymphadenopathy-non-SAE-NR-Mild52
Lymphopenia-non-SAE-NR-Mild10
Malaise-non-SAE-NR-Mild21
Malaise-non-SAE-R-Mild10
Medical Device Pain-non-SAE-NR-Mild20
Memory Impairment-non-SAE-NR-Mild10
Meniscus Injury-non-SAE-NR-Mild10
Menstrual Disorder-non-SAE-NR-Mod10
Mental Status Changes-SAE-NR-Sev10
Micturition Urgency-non-SAE-NR-Mild01
Middle Ear Effusion-non-SAE-NR-Mild01
Migraine-non-SAE-NR-Mild30
Migraine-non-SAE-NR-Mod24
Migraine-non-SAE-NR-Sev01
Migraine-non-SAE-R-Mild12
Migraine-non-SAE-R-Mod31
Mitral Valve Incompetence-non-SAE-NR-Mild20
Molluscum Contagiosum-non-SAE-NR-Mild11
Mouth Ulceration-non-SAE-NR-Mild01
Mucosal Inflammation-non-SAE-NR-Mild10
Muscle Contractions Involuntary-non-SAE-R-Mild10
Muscle Spasms-non-SAE-NR-Mild40
Muscle Strain-non-SAE-NR-Mild20
Muscular Weakness-non-SAE-NR-Mild01
Muscular Weakness-non-SAE-NR-Mod10
Musculoskeletal Pain-non-SAE-NR-Mild40
Musculoskeletal Pain-non-SAE-NR-Mod11
Myalgia-non-SAE-NR-Mild23
Myalgia-non-SAE-NR-Mod01
Myalgia-non-SAE-R-Mild233
Myalgia-non-SAE-R-Mod31
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (N-Z).

Categories presented as Preferred Term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relatedness to study drug: R (related to either study drug); NR (not related to either or both study drugs). Study drugs are Immune Globulin Subcutaneous Solution, 10% (IGSC, 10%) and recombinant human hyaluronidase (rHuPH20) Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Infection - Inf.

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to the Study Drug, and Severity (N-Z).
Number of AEsIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Nasal Congestion-non-SAE-NR-Mild115
Nasal Congestion-non-SAE-NR-Mod20
Nasal Discomfort-non-SAE-NR-Mild10
Nasopharyngitis-non-SAE-NR-Mild75
Nasopharyngitis-non-SAE-NR-Mod10
Nausea-non-SAE-NR-Mild145
Nausea-non-SAE-NR-Mod41
Nausea-non-SAE-R-Mild2512
Nausea-non-SAE-R-Mod37
Nephrolithiasis-non-SAE-NR-Mild01
Nerve Compression-non-SAE-NR-Mild01
Neutrophil Count Decreased-non-SAE-NR-Mild01
Ocular Hyperaemia-non-SAE-NR-Mild01
Oedema Peripheral-non-SAE-NR-Mild44
Oedema Peripheral-non-SAE-NR-Mod41
Oedema Peripheral-non-SAE-R-Mild01
Oral Candidiasis-non-SAE-NR-Mild20
Oral Herpes-non-SAE-NR-Mild72
Oral Pain-non-SAE-NR-Mild01
Oral Pain-non-SAE-NR-Mod01
Orchitis-non-SAE-NR-Mod10
Oropharyngeal Pain-non-SAE-NR-Mild41
Osteoarthritis-non-SAE-NR-Mild21
Osteoarthritis-non-SAE-NR-Mod10
Osteopenia-non-SAE-NR-Mild10
Osteoporosis-non-SAE-NR-Mild01
Otitis Externa-non-SAE-NR-Mild11
Otitis Externa-non-SAE-NR-Mod01
Otitis Media-non-SAE-NR-Mod11
Pain-non-SAE-NR-Mild20
Pain-non-SAE-R-Mild70
Pain In Extremity-non-SAE-NR-Mild41
Pain In Extremity-non-SAE-R-Sev01
Palpitations-non-SAE-NR-Mild20
Panic Attack-non-SAE-NR-Mild01
Papule-non-SAE-NR-Mild10
Paraesthesia-non-SAE-R-Mild10
Paranasal Cyst-non-SAE-NR-Mild10
Pelvic Pain-non-SAE-NR-Mod10
Pericardial Effusion-non-SAE-NR-Mild10
Perineurial Cyst-non-SAE-NR-Mod10
Periodontal Disease-non-SAE-NR-Mild10
Pharyngitis-non-SAE-NR-Mild61
Pharyngitis-non-SAE-NR-Mod01
Pharyngitis Streptococcal-non-SAE-NR-Mild10
Pleural Effusion-non-SAE-NR-Mild10
Pleural Effusion-non-SAE-NR-Mod10
Pneumonia-non-SAE-NR-Mild10
Pneumonia Bacterial-non-SAE-NR-Mod10
Pneumonia Pseudomonas Aeruginosa-SAE-NR-Sev10
Pollakiuria-non-SAE-NR-Mild01
Pollakiuria-non-SAE-NR-Mod10
Polycystic Ovaries-non-SAE-NR-Mild01
Post Procedural Complication-non-SAE-NR-Mod10
Post Procedural Haemorrhage-non-SAE-NR-Mild10
Post Procedural Swelling-non-SAE-NR-Mild10
Procedural Nausea-non-SAE-NR-Mod10
Procedural Pain-non-SAE-NR-Mild01
Procedural Pain-non-SAE-NR-Mod91
Proctalgia-non-SAE-NR-Mod10
Productive Cough-non-SAE-NR-Mild20
Protein Urine Present-non-SAE-NR-Mild10
Pruritus-non-SAE-NR-Mild33
Pruritus-non-SAE-NR-Mod10
Pruritus-non-SAE-R-Mild03
Pruritus Allergic-non-SAE-NR-Mod01
Pruritus Generalised-non-SAE-R-Mild01
Pulmonary Hypertension-non-SAE-NR-Mild10
Pulmonary Hypertension-non-SAE-NR-Mod10
Pulmonary Vascular Disorder-non-SAE-NR-Mod10
Puncture Site Pain-non-SAE-NR-Mild01
Puncture Site Pain-non-SAE-NR-Mod02
Purpura Senile-non-SAE-NR-Mild01
Pyogenic Granuloma-non-SAE-NR-Mod11
Pyrexia-non-SAE-NR-Mild115
Pyrexia-non-SAE-NR-Mod20
Pyrexia-non-SAE-R-Mild30
Pyuria-non-SAE-NR-Mild01
Rales-non-SAE-NR-Mod11
Rash-non-SAE-NR-Mild21
Rash Generalised-non-SAE-R-Mild01
Rectal Polyp-non-SAE-NR-Mod10
Red Blood Cells Urine Positive-non-SAE-NR-Mild10
Respiratory Tract Congestion-non-SAE-NR-Mild20
Respiratory Tract Congestion-non-SAE-NR-Mod10
Respiratory Tract Infection-non-SAE-NR-Mild10
Respiratory Tract Infection-non-SAE-NR-Mod10
Restless Legs Syndrome-non-SAE-NR-Mild10
Rhinitis-non-SAE-NR-Mild20
Rhinitis Perennial-non-SAE-NR-Mild10
Rhinorrhoea-non-SAE-NR-Mild21
Rhinorrhoea-non-SAE-R-Mild01
Right Atrial Dilatation-non-SAE-NR-Mild10
Rotator Cuff Syndrome-non-SAE-NR-Mild10
Scab-non-SAE-NR-Mild10
Scar-non-SAE-NR-Mild10
Scoliosis-non-SAE-NR-Mild01
Scratch-non-SAE-NR-Mild10
Scrotal Swelling-non-SAE-R-Mild30
Seborrhoeic Keratosis-non-SAE-NR-Mod20
Sinus Congestion-non-SAE-NR-Mild11
Sinus Headache-non-SAE-NR-Mild20
Sinusitis-non-SAE-NR-Mild343
Sinusitis-non-SAE-NR-Mod2913
Skin Hyperpigmentation-non-SAE-NR-Mild10
Skin Lesion-non-SAE-NR-Mild10
Skin Mass-non-SAE-NR-Mild11
Sleep Apnoea Syndrome-non-SAE-NR-Mild10
Slow Speech-non-SAE-NR-Mod10
Solar Lentigo-non-SAE-NR-Mild10
Somnolence-non-SAE-NR-Mild10
Speech Disorder-non-SAE-NR-Mild01
Spermatocele-non-SAE-NR-Mild10
Spinal Compression Fracture-non-SAE-NR-Mod10
Spinal Meningeal Cyst-SAE-NR-Sev10
Spinal Osteoarthritis-non-SAE-NR-Mild30
Squamous Cell Carcinoma-non-SAE-NR-Mod42
Stress-non-SAE-NR-Mod10
Suicide Attempt-non-SAE-NR-Sev10
Sunburn-non-SAE-NR-Mild10
Swelling Face-non-SAE-NR-Mod10
Swelling Face-non-SAE-NR-Sev01
Swollen Tongue-non-SAE-NR-Mild10
Synovial Cyst-non-SAE-NR-Mild10
Tachycardia-non-SAE-NR-Mild51
Tachycardia-non-SAE-Mod10
Tendon Disorder-non-SAE-NR-Sev10
Tendonitis-non-SAE-NR-Mild20
Tendonitis-non-SAE-NR-Mod10
Testicular Microlithiasis-non-SAE-NR-Mild10
Testicular Pain-non-SAE-NR-Mod10
Thermal Burn-non-SAE-NR-Mild01
Thinking Abnormal-non-SAE-NR-Mod10
Thrombocytopenia-non-SAE-NR-Mild10
Tibia Fracture-non-SAE-NR-Sev10
Tinea Cruris-non-SAE-NR-Mild10
Tinea Infection-non-SAE-NR-Mild10
Tooth Abscess-non-SAE-NR-Mild01
Tooth Abscess-non-SAE-NR-Mod01
Tooth Fracture-non-SAE-NR-Mod10
Tooth Infection-non-SAE-NR-Mild10
Tooth Infection-non-SAE-NR-Mod10
Toothache-non-SAE-NR-Mod01
Toxicity To Various Agents-SAE-NR-Sev10
Tracheal Stenosis-non-SAE-NR-Mild01
Transient Ischaemic Attack-SAE-NR-Mod01
Traumatic Haematoma-non-SAE-NR-Mild10
Tricuspid Valve Incompetence-non-SAE-NR-Mild10
Trigeminal Neuralgia-non-SAE-NR-Mild10
Tympanic Membrane Scarring-non-SAE-NR-Mild10
Type 2 Diabetes Mellitus-non-SAE-NR-Mod20
Upper Limb Fracture-non-SAE-NR-Mod10
Upper Limb Fracture-non-SAE-NR-Sev10
Upper Respiratory Tract Infection-non-SAE-NR-Mild168
Upper Respiratory Tract Infection-non-SAE-NR-Mod132
Upper-Airway Cough Syndrome-non-SAE-NR-Mild11
Urethritis-non-SAE-NR-Mild10
Urinary Tract Infection-non-SAE-NR-Mild44
Urinary Tract Infection-non-SAE-NR-Mod62
Urticaria-non-SAE-NR-Mild01
Urticaria-non-SAE-R-Mild01
Uterine Polyp-non-SAE-NR-Mod10
Vaginal Prolapse-SAE-NR-Mod10
Vaginitis Bacterial-non-SAE-NR-Mild20
Varicose Vein-non-SAE-NR-Mild10
Vasomotor Rhinitis-non-SAE-NR-Mild10
Vein Pain-non-SAE-NR-Mild01
Ventricular Hypokinesia-non-SAE-NR-Mild10
Vessel Puncture Site Bruise-non-SAE-NR-Mild10
Viral Infection-non-SAE-NR-Mild30
Viral Infection-non-SAE-NR-Mod01
Viral Pharyngitis-non-SAE-NR-Mild10
Viral Pharyngitis-non-SAE-NR-Mod01
Viral Rash-non-SAE-NR-Mod10
Viral Upper Respiratory Tract Inf.-non-SAE-NR-Mild295
Viral Upper Respiratory Tract Inf.-non-SAE-NR-Mod11
Vision Blurred-non-SAE-NR-Mild10
Vitamin B12 Deficiency-non-SAE-NR-Mild10
Vitamin D Decreased-non-SAE-NR-Mild01
Vitamin D Deficiency-non-SAE-NR-Mild20
Vitamin D Deficiency-non-SAE-NR-Mod10
Vomiting-non-SAE-NR-Mild132
Vomiting-non-SAE-NR-Mod41
Vomiting-non-SAE-R-Mod01
Vulvar Dysplasia-non-SAE-NR-Mild20
Vulvovaginal Candidiasis-non-SAE-NR-Mild10
Vulvovaginal Mycotic Infection-non-SAE-NR-Mild41
Vulvovaginal Mycotic Infection-non-SAE-NR-Mod20
Wheezing-non-SAE-NR-Mod10
Wisdom Teeth Removal-non-SAE-NR-Mild10
Wisdom Teeth Removal-non-SAE-NR-Sev10
Wound-non-SAE-NR-Mild01
Wrist Fracture-non-SAE-NR-Mod01
Xeroderma-non-SAE-NR-Mild10
SecondaryRate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).

Categories presented as Preferred Term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per participant
Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).
Number of AEs per participantIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Abdominal Distension-non-SAE-Mild0.0950
Abdominal Hernia-non-SAE-Mild0.0160
Abdominal Mass-non-SAE-Mild00.020
Abdominal Pain-non-SAE-Mild0.0320.078
Abdominal Pain-non-SAE-Mod0.0630
Abdominal Pain-non-SAE-Severe0.0160
Abdominal Pain Upper-non-SAE-Mild0.1270
Abdominal Tenderness-non-SAE-Mild0.0480
Abnormal Loss of Weight-non-SAE-Mild0.0160
Acarodermatitis-non-SAE-Mild0.0320.020
Acarodermatitis-non-SAE-Mod0.0320
Acne-non-SAE-Mild0.0160
Acne-non-SAE-Mod0.0160
Actinic Keratosis-non-SAE-Mild0.0160
Actinic Keratosis-non-SAE-Mod0.0160.039
Activities of Daily Living Impaired-non-SAE-Mod0.0160
Acute Sinusitis-non-SAE-Mild00.020
Acute Sinusitis-non-SAE-Mod0.0160
Acute Stress Disorder-non-SAE-Mild0.0160
Adhesiolysis-SAE-Mod0.0160
Age-Related Macular Degeneration-non-SAE-Mild0.0160
Agitation-non-SAE-Mild0.0160
Aldolase Increased-non-SAE-Mild0.0160
Anaphylactic Reaction-non-SAE-Sev00.020
Animal Bite-non-SAE-Mild0.0160
Animal Scratch-non-SAE-Mild00.020
Anxiety-non-SAE-Mild0.0320
Anxiety-non-SAE-Mod0.0320
Aortic Calcification-non-SAE-Mild0.0160
Aortic Stenosis-non-SAE-Mild0.0160
Aortic Stenosis-non-SAE-Mod0.0160
Aortic Valve Incompetence-non-SAE-Mod0.0160
Aortic Valve Incompetence-SAE-Sev0.0160
Aphthous Stomatitis-non-SAE-Mild0.0790.039
Aphthous Stomatitis-non-SAE-Mod0.0320
Appendicitis-SAE-Mod0.0160
Application Site Erythema-non-SAE-Mild0.0160
Arteritis-non-SAE-Mod0.0160
Arthralgia-non-SAE-Mild0.1270.020
Arthralgia-non-SAE-Mod00.118
Arthropod Bite-non-SAE-Mild0.0160.020
Asthenia-non-SAE-Mild0.1110
Asthenia-non-SAE-Mod0.1430.020
Asthma-non-SAE-Mild0.1900.059
Asthma-non-SAE-Mod0.3170.059
Ataxia-non-SAE-Mild0.0320
Atelectasis-non-SAE-Mild0.0160
Atrial Fibrillation-non-SAE-Mild0.0160
Atrial Fibrillation-SAE-Mod0.0160
ADHD-non-SAE-Mod0.0160
Back Pain-non-SAE-Mild0.0480.039
Back Pain-non-SAE-Mod0.0480.039
Back Pain-non-SAE-Sev00.020
Basal Cell Carcinoma-non-SAE-Mild0.0160
Basal Cell Carcinoma-non-SAE-Mod0.0630.020
Blepharochalasis-non-SAE-Mild0.0160
Blister-non-SAE-Mild0.0160
Blood Bicarbonate Decreased-non-SAE-Mild0.0160
Blood Creatine Phosphokinase Inc.-non-SAE-Mild0.0480
Blood Creatine Phosphokinase Inc.-non-SAE-Mod0.0320
Blood Creatinine Increased-non-SAE-Mild0.0160.020
Blood Glucose Increased-non-SAE-Mild0.0630.020
Blood Urea Increased-non-SAE-Mild00.020
Blood Urine Present-non-SAE-Mild0.0320
Body Tinea-non-SAE-Mild0.0320
Bone Pain-non-SAE-Mild0.0160
Breast Calcifications-non-SAE-Mild0.0160
Breast Dysplasia-non-SAE-Mild00.020
Bronchiolitis-non-SAE-Mild0.0160
Bronchitis-non-SAE-Mild0.1750.098
Bronchitis-non-SAE-Mod0.1750.039
Burns Second Degree-non-SAE-Mild0.0160
Bursitis-non-SAE-Mild0.0320
Candidiasis-non-SAE-Mild0.0160
Cardiac Failure Congestive-SAE-Mild0.0160
Cardiac Murmur-non-SAE-Mild0.0320
Cardiomegaly-non-SAE-Mild00.020
Cardiomegaly-non-SAE-Mod0.0320
Cardiomyopathy-non-SAE-Mild0.0160
Cataract-non-SAE-Mild0.0160.020
Cataract-non-SAE-Mod0.0320
Cellulitis-non-SAE-Mild0.0320
Cellulitis-non-SAE-Mod0.0320.020
Cellulitis-SAE-Mod00.020
Cellulitis Of Male Ext Genital Organ-non-SAE-Mod0.0160
Cerebral Small Vessel Ischaemic Dis.-non-SAE-Mild0.0160
Cerumen Impaction-non-SAE-Mild0.0320.039
Cervical Spinal Stenosis-non-SAE-Mild00.020
Chapped Lips-non-SAE-Mild0.0160
Cheilitis-non-SAE-Mild0.0160
Chest Discomfort-non-SAE-Mild0.0160
Chest Pain-non-SAE-Mild0.0320
Chest Pain-non-SAE-Mod0.0160
Chills-non-SAE-Mild0.2060.020
Chills-non-SAE-Mod0.0160
Cholelithiasis-non-SAE-Mild0.0320
Chondromalacia-non-SAE-Mod0.0160
Chromaturia-non-SAE-Mild0.0160
COPD-non-SAE-Mild0.0320
COPD-non-SAE-Mod0.0480
COPD-SAE-Mod0.0160
COPD-SAE-Sev0.0160
Chronic Sinusitis-non-SAE-Mild0.0790.039
Chronic Sinusitis-non-SAE-Mod0.0480.020
Conjunctival Haemorrhage-non-SAE-Mild0.0160
Conjunctival Hyperaemia-non-SAE-Mild0.0320
Conjunctivitis-non-SAE-Mild00.039
Conjunctivitis Allergic-non-SAE-Mild0.0160.020
Conjunctivitis Allergic-non-SAE-Mod00.039
Conjunctivitis Infective-non-SAE-Mild0.0480.020
Constipation-non-SAE-Mild0.0480.059
Constipation-non-SAE-Mod0.0480
Contusion-non-SAE-Mild00.059
Convulsion-non-SAE-Mild0.0160
Convulsion-non-SAE-Mod0.0320.020
Coombs Direct Test Positive-non-SAE-Mild0.0160
Coombs Test Positive-non-SAE-Mild0.0320
Corneal Abrasion-non-SAE-Mild0.0160
Costochondritis-non-SAE-Mild0.0160
Costochondritis-non-SAE-Sev0.0160
Cough-non-SAE-Mild0.1750.059
Cough-non-SAE-Mod0.0480.020
Cryptosporidiosis Infection-SAE-Sev0.0160
Cyst-non-SAE-Mild0.0160
Cyst-non-SAE-Mod0.0320
Cystitis-non-SAE-Mild0.0160
Cystocele-SAE-Mod0.0160
Decreased Appetite-non-SAE-Mild0.0630.157
Decreased Appetite-non-SAE-Mod0.0320
Dehydration-non-SAE-Mild0.0160
Dehydration-non-SAE-Mod0.0160
Dental Caries-non-SAE-Mild0.0320
Depression-non-SAE-Mild0.0160
Depression-non-SAE-Mod0.0480.020
Dermal Cyst-non-SAE-Mod0.0160
Dermatitis-non-SAE-Mild0.0160
Dermatitis Allergic-non-SAE-Mild00.020
Dermatitis Atopic-non-SAE-Mild0.0160
Dermatitis Contact-non-SAE-Mild0.0480
Dermatitis Contact-non-SAE-Mod0.0160
Dermatitis Psoriasiform-non-SAE-Sev0.0160
Device Breakage-non-SAE-Mod0.0160
Device Failure-non-SAE-Mod0.0160
Diarrhoea-non-SAE-Mild0.2700.098
Diarrhoea-non-SAE-Mod0.0320
Dizziness-non-SAE-Mild0.1590.020
Dizziness-non-SAE-Mod0.0160
Drug Eruption-non-SAE-Mod00.020
Drug Hypersensitivity-non-SAE-Mild0.0480
Dry Eye-non-SAE-Mild0.0160
Dry Eye-non-SAE-Mod0.0160.020
Dry Mouth-non-SAE-Mild00.020
Dry Skin-non-SAE-Mild00.020
Dysmenorrhoea-non-SAE-Mild0.0160
Dyspepsia-non-SAE-Mild00.059
Dysplastic Naevus-non-SAE-Mod0.0160
Dyspnoea-non-SAE-Mild0.0320.020
Dyspnoea-non-SAE-Mod0.0320
Dysuria-non-SAE-Mild0.0160.020
Dysuria-non-SAE-Mod0.0320
Ear Infection-non-SAE-Mild0.0160
Ear Infection-non-SAE-Mod0.0480
Ear Pain-non-SAE-Mild0.0160
Ear Pain-non-SAE-Mod0.0320
Ear Pruritus-non-SAE-Mild00.020
Ecchymosis-non-SAE-Mild0.0480
Ecchymosis-non-SAE-Mod00.020
Eczema-non-SAE-Mild00.039
Eczema-non-SAE-Mod0.0790
Empty Sella Syndrome-non-SAE-Mild0.0160
Epilepsy-non-SAE-Mod0.0160
Epistaxis-non-SAE-Mild0.1750.098
Erythema-non-SAE-Mild0.0160
Eschar-non-SAE-Mild0.0160
Excoriation-non-SAE-Mild0.1270.020
Excoriation-non-SAE-Mod0.0160
Eye Haemorrhage-non-SAE-Mild0.0160
Eye Infection-non-SAE-Mild0.0160.020
Eye Pain-non-SAE-Mild00.020
Eye Swelling-non-SAE-Mild0.0160
Eyelid Ptosis-non-SAE-Mild0.0160
Facial Bones Fracture-non-SAE-Mod00.020
Facial Pain-non-SAE-Mod0.0160
Fall-non-SAE-Mild0.0480.020
Fall-non-SAE-Sev00.020
Fatigue-non-SAE-Mild0.3170.294
Fatigue-non-SAE-Mod0.0950.157
Fatigue-non-SAE-Sev0.0160
Femur Fracture-SAE-Sev00.020
Fibromyalgia-non-SAE-Mod0.0320.020
Flatulence-non-SAE-Mod0.0160
Flushing-non-SAE-Mod00.020
Folliculitis-non-SAE-Mild0.0160
Food Poisoning-non-SAE-Mild0.0320
Food Poisoning-non-SAE-Mod0.0160
Foot Fracture-non-SAE-Mod0.0160
Free Haemoglobin Present-non-SAE-Mild0.0320
Free Haemoglobin Present-non-SAE-Mod0.0320
Frequent Bowel Movements-non-SAE-Mod0.0160
Fungal Infection-non-SAE-Mild0.0160.020
Fungal Skin Infection-non-SAE-Mild0.0160
SecondaryRate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).

Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per participant
Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).
Number of AEs per participantIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Gastric Stenosis-non-SAE-Mod0.0160
Gastritis-non-SAE-Mild0.0160
Gastroenteritis-non-SAE-Mild0.0480
Gastroenteritis-non-SAE-Mod0.0320
Gastroenteritis Salmonella-non-SAE-Mod0.0160
Gastroenteritis Viral-non-SAE-Mild0.0630.020
Gastroenteritis Viral-non-SAE-Mod0.0480.020
Gastrointestinal Viral Infection-non-SAE-Mild0.0160
Gastrooesophageal Reflux Disease-non-SAE-Mild0.0480
Gastrooesophageal Reflux Disease-non-SAE-Mod0.0160
Genital Herpes-non-SAE-Mild0.0320.039
Genital Herpes-non-SAE-Mod00.020
Gingival Erosion-non-SAE-Mild0.0160
Gingivitis-non-SAE-Mild0.0160
Glaucoma-non-SAE-Mod0.0160
Glycosuria-non-SAE-Mild0.0160
Gout-non-SAE-Mod0.0160
Haematochezia-non-SAE-Mild0.0160
Haematospermia-non-SAE-Mild0.0160
Haematuria-non-SAE-Mild0.0160.020
Haemoglobin Decreased-non-SAE-Mild00.020
Haemolysis-non-SAE-Mild0.0160
Haemorrhoids-non-SAE-Mild0.0320
Haemorrhoids-non-SAE-Mod0.0320
Hand Fracture-non-SAE-Mod0.0160
Headache-non-SAE-Mild0.6510.765
Headache-non-SAE-Mod0.0950.039
Heart Rate Irregular-non-SAE-Mild0.0320.020
Herpes Zoster-non-SAE-Mod0.0480
Hiatus Hernia-non-SAE-Mild0.0160
Hydrocele-non-SAE-Mild0.0160
Hypercapnia-non-SAE-Mild0.0160
Hypercholesterolaemia-non-SAE-Mild0.0160
Hypersensitivity-non-SAE-Mild0.0320
Hypertension-non-SAE-Mild0.0160.020
Hypertension-non-SAE-Mod0.0950
Hypertension-SAE-Mod0.0160
Hypoaesthesia-non-SAE-Mild0.0160
Hypokalaemia-non-SAE-Mild00.039
Hypothyroidism-non-SAE-Mild00.039
Hypothyroidism-non-SAE-Mod0.0160
Impetigo-non-SAE-Mild0.0320
Incision Site Pain-non-SAE-Mod0.0160
Increased Upper Airway Secretion-non-SAE-Mild0.0160
Inflammation Of Wound-non-SAE-Mild00.020
Influenza-non-SAE-Mod0.0950.078
Influenza Like Illness-non-SAE-Mild0.0480
Influenza Like Illness-non-SAE-Mod0.0160
Infusion Site Abscess-non-SAE-Mild0.0160
Infusion Site Bruising-non-SAE-Mild0.0160
Infusion Site Discolouration-non-SAE-Mild0.0160
Infusion Site Discomfort-non-SAE-Mild0.1270.039
Infusion Site Erythema-non-SAE-Mild0.3490
Infusion Site Erythema-non-SAE-Mod0.0160
Infusion Site Induration-non-SAE-Mild0.0320
Infusion Site Mass-non-SAE-Mild0.0160
Infusion Site Oedema-non-SAE-Mild0.0160
Infusion Site Pain-non-SAE-Mild1.2380.333
Infusion Site Pain-non-SAE-Mod0.0950.039
Infusion Site Pruritus-non-SAE-Mild0.4920
Infusion Site Swelling-non-SAE-Mild0.0480
Infusion Site Swelling-non-SAE-Sev0.0160
Injection Site Pain-non-SAE-Mild0.0480
Insomnia-non-SAE-Mild0.0790
Insomnia-non-SAE-Mod00.020
Intervertebral Disc Degeneration-non-SAE-Mild0.0160
Iron Deficiency Anaemia-non-SAE-Mild0.0160
Irritable Bowel Syndrome-non-SAE-Mod0.0320
Jejunal Stenosis-non-SAE-Mod0.0160
Joint Dislocation-non-SAE-Sev0.0160
Joint Injury-non-SAE-Mild0.0320
Joint Swelling-non-SAE-Mod00.020
Laceration-non-SAE-Mild00.020
Ligament Sprain-non-SAE-Mild0.0320
Ligament Sprain-non-SAE-Mod0.0160.039
Limb Discomfort-non-SAE-Mild00.020
Liver Function Test Abnormal-non-SAE-Mild0.0160
Local Swelling-non-SAE-Mild0.0480
Localised Infection-non-SAE-Mod0.0160
Loss Of Consciousness-non-SAE-Mild00.020
Lyme Disease-non-SAE-Mild0.0320
Lymph Gland Infection-non-SAE-Mod0.0160
Lymphadenitis-non-SAE-Mod00.020
Lymphadenitis Bacterial-non-SAE-Mild0.0320
Lymphadenopathy-non-SAE-Mild0.0790.039
Lymphopenia-non-SAE-Mild0.0160
Malaise-non-SAE-Mild0.0480.020
Medical Device Pain-non-SAE-Mild0.0320
Memory Impairment-non-SAE-Mild0.0160
Meniscus Injury-non-SAE-Mild0.0160
Menstrual Disorder-non-SAE-Mod0.0160
Mental Status Changes-SAE-Sev0.0160
Micturition Urgency-non-SAE-Mild00.020
Middle Ear Effusion-non-SAE-Mild00.020
Migraine-non-SAE-Mild0.0630.039
Migraine-non-SAE-Mod0.0790.098
Migraine-non-SAE-Sev00.020
Mitral Valve Incompetence-non-SAE-Mild0.0320
Molluscum Contagiosum-non-SAE-Mild0.0160.020
Mouth Ulceration-non-SAE-Mild00.020
Mucosal Inflammation-non-SAE-Mild0.0160
Muscle Contractions Involuntary-non-SAE-Mild0.0160
Muscle Spasms-non-SAE-Mild0.0630
Muscle Strain-non-SAE-Mild0.0320
Muscular Weakness-non-SAE-Mild00.020
Muscular Weakness-non-SAE-Mod0.0160
Musculoskeletal Pain-non-SAE-Mild0.0630
Musculoskeletal Pain-non-SAE-Mod0.0160.020
Myalgia-non-SAE-Mild0.3970.118
Myalgia-non-SAE-Mod0.0480.039
SecondaryRate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).

Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per participant
Rate of All AEs Per Participant Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).
Number of AEs per participantIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Nasal Congestion-non-SAE-Mild0.1750.098
Nasal Congestion-non-SAE-Mod0.0320
Nasal Discomfort-non-SAE-Mild0.0160
Nasopharyngitis-non-SAE-Mild0.1110.098
Nasopharyngitis-non-SAE-Mod0.0160
Nausea-non-SAE-Mild0.6190.333
Nausea-non-SAE-Mod0.1110.157
Nephrolithiasis-non-SAE-Mild00.020
Nerve Compression-non-SAE-Mild00.020
Neutrophil Count Decreased-non-SAE-Mild00.020
Ocular Hyperaemia-non-SAE-Mild00.020
Oedema Peripheral-non-SAE-Mild0.0630.098
Oedema Peripheral-non-SAE-Mod0.0630.020
Oral Candidiasis-non-SAE-Mild0.0320
Oral Herpes-non-SAE-Mild0.1110.039
Oral Pain-non-SAE-Mild00.020
Oral Pain-non-SAE-Mod00.020
Orchitis-non-SAE-Mod0.0160
Oropharyngeal Pain-non-SAE-Mild0.0630.020
Osteoarthritis-non-SAE-Mild0.0320.020
Osteoarthritis-non-SAE-Mod0.0160
Osteopenia-non-SAE-Mild0.0160
Osteoporosis-non-SAE-Mild00.020
Otitis Externa-non-SAE-Mild0.0160.020
Otitis Externa-non-SAE-Mod00.020
Otitis Media-non-SAE-Mod0.0160.020
Pain-non-SAE-Mild0.1430
Pain In Extremity-non-SAE-Mild0.0630.020
Pain In Extremity-non-SAE-Sev00.020
Palpitations-non-SAE-Mild0.0320
Panic Attack-non-SAE-Mild00.020
Papule-non-SAE-Mild0.0160
Paraesthesia-non-SAE-Mild0.0160
Paranasal Cyst-non-SAE-Mild0.0160
Pelvic Pain-non-SAE-Mod0.0160
Pericardial Effusion-non-SAE-Mild0.0160
Perineurial Cyst-non-SAE-Mod0.0160
Periodontal Disease-non-SAE-Mild0.0160
Pharyngitis-non-SAE-Mild0.0950.020
Pharyngitis-non-SAE-Mod00.020
Pharyngitis Streptococcal-non-SAE-Mild0.0160
Pleural Effusion-non-SAE-Mild0.0160
Pleural Effusion-non-SAE-Mod0.0160
Pneumonia-non-SAE-Mild0.0160
Pneumonia Bacterial-non-SAE-Mod0.0160
Pneumonia Pseudomonas Aeruginosa-SAE-Sev0.0160
Pollakiuria-non-SAE-Mild00.020
Pollakiuria-non-SAE-Mod0.0160
Polycystic Ovaries-non-SAE-Mild00.020
Post Procedural Complication-non-SAE-Mod0.0160
Post Procedural Haemorrhage-non-SAE-Mild0.0160
Post Procedural Swelling-non-SAE-Mild0.0160
Procedural Nausea-non-SAE-Mod0.0160
Procedural Pain-non-SAE-Mild00.020
Procedural Pain-non-SAE-Mod0.1430.020
Proctalgia-non-SAE-Mod0.0160
Productive Cough-non-SAE-Mild0.0320
Protein Urine Present-non-SAE-Mild0.0160
Pruritus-non-SAE-Mild0.0480.118
Pruritus-non-SAE-Mod0.0160
Pruritus Allergic-non-SAE-Mod00.020
Pruritus Generalised-non-SAE-Mild00.020
Pulmonary Hypertension-non-SAE-Mild0.0160
Pulmonary Hypertension-non-SAE-Mod0.0160
Pulmonary Vascular Disorder-non-SAE-Mod0.0160
Puncture Site Pain-non-SAE-Mild00.020
Puncture Site Pain-non-SAE-Mod00.039
Purpura Senile-non-SAE-Mild00.020
Pyogenic Granuloma-non-SAE-Mod0.0160.020
Pyrexia-non-SAE-Mild0.2220.098
Pyrexia-non-SAE-Mod0.0320
Pyuria-non-SAE-Mild00.020
Rales-non-SAE-Mod0.0160.020
Rash-non-SAE-Mild0.0320.020
Rash Generalised-non-SAE-Mild00.020
Rectal Polyp-non-SAE-Mod0.0160
Red Blood Cells Urine Positive-non-SAE-Mild0.0160
Respiratory Tract Congestion-non-SAE-Mild0.0320
Respiratory Tract Congestion-non-SAE-Mod0.0160
Respiratory Tract Infection-non-SAE-Mild0.0160
Respiratory Tract Infection-non-SAE-Mod0.0160
Restless Legs Syndrome-non-SAE-Mild0.0160
Rhinitis-non-SAE-Mild0.0320
Rhinitis Perennial-non-SAE-Mild0.0160
Rhinorrhoea-non-SAE-Mild0.0320.039
Right Atrial Dilatation-non-SAE-Mild0.0160
Rotator Cuff Syndrome-non-SAE-Mild0.0160
Scab-non-SAE-Mild0.0160
Scar-non-SAE-Mild0.0160
Scoliosis-non-SAE-Mild00.020
Scratch-non-SAE-Mild0.0160
Scrotal Swelling-non-SAE-Mild0.0480
Seborrhoeic Keratosis-non-SAE-Mod0.0320
Sinus Congestion-non-SAE-Mild0.0160.020
Sinus Headache-non-SAE-Mild0.0320
Sinusitis-non-SAE-Mild0.5400.059
Sinusitis-non-SAE-Mod0.4600.255
Skin Hyperpigmentation-non-SAE-Mild0.0160
Skin Lesion-non-SAE-Mild0.0160
Skin Mass-non-SAE-Mild0.0160.020
Sleep Apnoea Syndrome-non-SAE-Mild0.0160
Slow Speech-non-SAE-Mod0.0160
Solar Lentigo-non-SAE-Mild0.0160
Somnolence-non-SAE-Mild0.0160
Speech Disorder-non-SAE-Mild00.020
Spermatocele-non-SAE-Mild0.0160
Spinal Compression Fracture-non-SAE-Mod0.0160
Spinal Meningeal Cyst-SAE-Sev0.0160
Spinal Osteoarthritis-non-SAE-Mild0.0480
Squamous Cell Carcinoma-non-SAE-Mod0.0630.039
Stress-non-SAE-Mod0.0160
Suicide Attempt-non-SAE-Sev0.0160
Sunburn-non-SAE-Mild0.0160
Swelling Face-non-SAE-Mod0.0160
Swelling Face-non-SAE-Sev00.020
Swollen Tongue-non-SAE-Mild0.0160
Synovial Cyst-non-SAE-Mild0.0160
Tachycardia-non-SAE-Mild0.0790.020
Tachycardia-non-SAE-Mod0.0160
Tendon Disorder-non-SAE-Sev0.0160
Tendonitis-non-SAE-Mild0.0320
Tendonitis-non-SAE-Mod0.0160
Testicular Microlithiasis-non-SAE-Mild0.0160
Testicular Pain-non-SAE-Mod0.0160
Thermal Burn-non-SAE-Mild00.020
Thinking Abnormal-non-SAE-Mod0.0160
Thrombocytopenia-non-SAE-Mild0.0160
Tibia Fracture-non-SAE-Sev0.0160
Tinea Cruris-non-SAE-Mild0.0160
Tinea Infection-non-SAE-Mild0.0160
Tooth Abscess-non-SAE-Mild00.020
Tooth Abscess-non-SAE-Mod00.020
Tooth Fracture-non-SAE-Mod0.0160
Tooth Infection-non-SAE-Mild0.0160
Tooth Infection-non-SAE-Mod0.0160
Toothache-non-SAE-Mod00.020
Toxicity To Various Agents-SAE-Sev0.0160
Tracheal Stenosis-non-SAE-Mild00.020
Transient Ischaemic Attack-SAE-Mod00.020
Traumatic Haematoma-non-SAE-Mild0.0160
Tricuspid Valve Incompetence-non-SAE-Mild0.0160
Trigeminal Neuralgia-non-SAE-Mild0.0160
Tympanic Membrane Scarring-non-SAE-Mild0.0160
Type 2 Diabetes Mellitus-non-SAE-Mod0.0320
Upper Limb Fracture-non-SAE-Mod0.0160
Upper Limb Fracture-non-SAE-Sev0.0160
Upper Respiratory Tract Infection-non-SAE-Mild0.2540.157
Upper Respiratory Tract Infection-non-SAE-Mod0.2060.039
Upper-Airway Cough Syndrome-non-SAE-Mild0.0160.020
Urethritis-non-SAE-Mild0.0160
Urinary Tract Infection-non-SAE-Mild0.0630.078
Urinary Tract Infection-non-SAE-Mod0.0950.039
Urticaria-non-SAE-Mild00.039
Uterine Polyp-non-SAE-Mod0.0160
Vaginal Prolapse-SAE-Mod0.0160
Vaginitis Bacterial-non-SAE-Mild0.0320
Varicose Vein-non-SAE-Mild0.0160
Vasomotor Rhinitis-non-SAE-Mild0.0160
Vein Pain-non-SAE-Mild00.020
Ventricular Hypokinesia-non-SAE-Mild0.0160
Vessel Puncture Site Bruise-non-SAE-Mild0.0160
Viral Infection-non-SAE-Mild0.0480
Viral Infection-non-SAE-Mod00.020
Viral Pharyngitis-non-SAE-Mild0.0160
Viral Pharyngitis-non-SAE-Mod00.020
Viral Rash-non-SAE-Mod0.0160
Viral Upper Respiratory Tract Inf.-non-SAE-Mild0.4600.098
Viral Upper Respiratory Tract Inf-non-SAE-Mod0.0160.020
Vision Blurred-non-SAE-Mild0.0160
Vitamin B12 Deficiency-non-SAE-Mild0.0160
Vitamin D Decreased-non-SAE-Mild00.020
Vitamin D Deficiency-non-SAE-Mild0.0320
Vitamin D Deficiency-non-SAE-Mod0.0160
Vomiting-non-SAE-Mild0.2060.039
Vomiting-non-SAE-Mod0.0630.039
Vulvar Dysplasia-non-SAE-Mild0.0320
Vulvovaginal Candidiasis-non-SAE-Mild0.0160
Vulvovaginal Mycotic Infection-non-SAE-Mild0.0630.020
Vulvovaginal Mycotic Infection-non-SAE-Mod0.0320
Wheezing-non-SAE-Mod0.0160
Wisdom Teeth Removal-non-SAE-Mild0.0160
Wisdom Teeth Removal-non-SAE-Sev0.0160
Wound-non-SAE-Mild00.020
Wrist Fracture-non-SAE-Mod00.020
Xeroderma-non-SAE-Mild0.0160
SecondaryRate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).

Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious adverse event; SAE- serious adverse event Severity: Mild; Mod (Moderate); Sev (Severe) Preferred terms abbreviated: ADHD - Attention Deficit/Hyperactivity Disorder COPD - Chronic Obstructive Pulmonary Disease Other abbreviations: Inc. - Increased Dis. - Disease

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per infusion
Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (A-F).
Number of AEs per infusionIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Abdominal Distension-non-SAE-Mild0.0040
Abdominal Hernia-non-SAE-Mild0.0010
Abdominal Mass-non-SAE-Mild0.0020
Abdominal Pain-non-SAE-Mild0.0010.007
Abdominal Pain-non-SAE-Mod0.0030
Abdominal Pain-non-SAE-Severe0.0010
Abdominal Pain Upper-non-SAE-Mild0.0050
Abdominal Tenderness-non-SAE-Mild0.0020
Abnormal Loss of Weight-non-SAE-Mild0.0010
Acarodermatitis-non-SAE-Mild0.0010.002
Acarodermatitis-non-SAE-Mod0.0010
Acne-non-SAE-Mild0.0010
Acne-non-SAE-Mod0.0010
Actinic Keratosis-non-SAE-Mild0.0010
Actinic Keratosis-non-SAE-Mod0.0010.003
Activities of Daily Living Impaired-non-SAE-Mod0.0010
Acute Sinusitis-non-SAE-Mild00.002
Acute Sinusitis-non-SAE-Mod0.0010
Acute Stress Disorder-non-SAE-Mild0.0010
Adhesiolysis-SAE-Mod0.0010
Age-Related Macular Degeneration-non-SAE-Mild0.0010
Agitation-non-SAE-Mild0.0010
Aldolase Increased-non-SAE-Mild0.0010
Anaphylactic Reaction-non-SAE-Sev00.002
Animal Bite-non-SAE-Mild0.0010
Animal Scratch-non-SAE-Mild00.002
Anxiety-non-SAE-Mild0.0010
Anxiety-non-SAE-Mod0.0010
Aortic Calcification-non-SAE-Mild0.0010
Aortic Stenosis-non-SAE-Mild0.0010
Aortic Stenosis-non-SAE-Mod0.0010
Aortic Valve Incompetence-non-SAE-Mod0.0010
Aortic Valve Incompetence-SAE-Sev0.0010
Aphthous Stomatitis-non-SAE-Mild0.0030.003
Aphthous Stomatitis-non-SAE-Mod0.0010
Appendicitis-SAE-Mod0.0010
Application Site Erythema-non-SAE-Mild0.0010
Arteritis-non-SAE-Mod0.0010
Arthralgia-non-SAE-Mild0.0050.002
Arthralgia-non-SAE-Mod00.010
Arthropod Bite-non-SAE-Mild0.0010.002
Asthenia-non-SAE-Mild0.0040
Asthenia-non-SAE-Mod0.0060.002
Asthma-non-SAE-Mild0.0080.005
Asthma-non-SAE-Mod0.0130.005
Ataxia-non-SAE-Mild0.0010
Atelectasis-non-SAE-Mild0.0010
Atrial Fibrillation-non-SAE-Mild0.0010
Atrial Fibrillation-SAE-Mod0.0010
ADHD-non-SAE-Mod0.0010
Back Pain-non-SAE-Mild0.0020.003
Back Pain-non-SAE-Mod0.0020.003
Back Pain-non-SAE-Sev00.002
Basal Cell Carcinoma-non-SAE-Mild0.0010
Basal Cell Carcinoma-non-SAE-Mod0.0030.002
Blepharochalasis-non-SAE-Mild0.0010
Blister-non-SAE-Mild0.0010
Blood Bicarbonate Decreased-non-SAE-Mild0.0010
Blood Creatine Phosphokinase Inc.-non-SAE-Mild0.0020
Blood Creatine Phosphokinase Inc.-non-SAE-Mod0.0010
Blood Creatinine Increased-non-SAE-Mild0.0010.002
Blood Glucose Increased-non-SAE-Mild0.0030.002
Blood Urea Increased-non-SAE-Mild00.002
Blood Urine Present-non-SAE-Mild0.0010
Body Tinea-non-SAE-Mild0.0010
Bone Pain-non-SAE-Mild0.0010
Breast Calcifications-non-SAE-Mild0.0010
Breast Dysplasia-non-SAE-Mild00.002
Bronchiolitis-non-SAE-Mild0.0010
Bronchitis-non-SAE-Mild0.0070.008
Bronchitis-non-SAE-Mod0.0070.003
Burns Second Degree-non-SAE-Mild0.0010
Bursitis-non-SAE-Mild0.0010
Candidiasis-non-SAE-Mild0.0010
Cardiac Failure Congestive-SAE-Mild0.0010
Cardiac Murmur-non-SAE-Mild0.0010
Cardiomegaly-non-SAE-Mild00.002
Cardiomegaly-non-SAE-Mod0.0010
Cardiomyopathy-non-SAE-Mild0.0010
Cataract-non-SAE-Mild0.0010.002
Cataract-non-SAE-Mod0.0010
Cellulitis-non-SAE-Mild0.0010
Cellulitis-non-SAE-Mod0.0010.002
Cellulitis-SAE-Mod00.002
Cellulitis Of Male Ext Genital Organ-non-SAE-Mod0.0010
Cerebral Small Vessel Ischaemic Dis.-non-SAE-Mild0.0010
Cerumen Impaction-non-SAE-Mild0.0010.003
Cervical Spinal Stenosis-non-SAE-Mild00.002
Chapped Lips-non-SAE-Mild0.0010
Cheilitis-non-SAE-Mild0.0010
Chest Discomfort-non-SAE-Mild0.0010
Chest Pain-non-SAE-Mild0.0010
Chest Pain-non-SAE-Mod0.0010
Chills-non-SAE-Mild0.0080.002
Chills-non-SAE-Mod0.0010
Cholelithiasis-non-SAE-Mild0.0010
Chondromalacia-non-SAE-Mod0.0010
Chromaturia-non-SAE-Mild0.0010
COPD-non-SAE-Mild0.0010
COPD-non-SAE-Mod0.0020
COPD-SAE-Mod0.0010
COPD-SAE-Sev0.0010
Chronic Sinusitis-non-SAE-Mild0.0030.003
Chronic Sinusitis-non-SAE-Mod0.0020.002
Conjunctival Haemorrhage-non-SAE-Mild0.0010
Conjunctival Hyperaemia-non-SAE-Mild0.0010
Conjunctivitis-non-SAE-Mild00.003
Conjunctivitis Allergic-non-SAE-Mild0.0010.002
Conjunctivitis Allergic-non-SAE-Mod00.003
Conjunctivitis Infective-non-SAE-Mild0.0020.002
Constipation-non-SAE-Mild0.0020.005
Constipation-non-SAE-Mod0.0020
Contusion-non-SAE-Mild00.005
Convulsion-non-SAE-Mild0.0010
Convulsion-non-SAE-Mod0.0010.002
Coombs Direct Test Positive-non-SAE-Mild0.0010
Coombs Test Positive-non-SAE-Mild0.0010
Corneal Abrasion-non-SAE-Mild0.0010
Costochondritis-non-SAE-Mild0.0010
Costochondritis-non-SAE-Sev0.0010
Cough-non-SAE-Mild0.0070.005
Cough-non-SAE-Mod0.0020.002
Cryptosporidiosis Infection-SAE-Sev0.0010
Cyst-non-SAE-Mild0.0010
Cyst-non-SAE-Mod0.0010
Cystitis-non-SAE-Mild0.0010
Cystocele-SAE-Mod0.0010
Decreased Appetite-non-SAE-Mild0.0030.013
Decreased Appetite-non-SAE-Mod0.0010
Dehydration-non-SAE-Mild0.0010
Dehydration-non-SAE-Mod0.0010
Dental Caries-non-SAE-Mild0.0010
Depression-non-SAE-Mild0.0010
Depression-non-SAE-Mod0.0020.002
Dermal Cyst-non-SAE-Mod0.0010
Dermatitis-non-SAE-Mild0.0010
Dermatitis Allergic-non-SAE-Mild00.002
Dermatitis Atopic-non-SAE-Mild0.0010
Dermatitis Contact-non-SAE-Mild0.0020
Dermatitis Contact-non-SAE-Mod0.0010
Dermatitis Psoriasiform-non-SAE-Sev0.0010
Device Breakage-non-SAE-Mod0.0010
Device Failure-non-SAE-Mod0.0010
Diarrhoea-non-SAE-Mild0.0110.008
Diarrhoea-non-SAE-Mod0.0010
Dizziness-non-SAE-Mild0.0060.002
Dizziness-non-SAE-Mod0.0010
Drug Eruption-non-SAE-Mod00.002
Drug Hypersensitivity-non-SAE-Mild0.0020
Dry Eye-non-SAE-Mild0.0010
Dry Eye-non-SAE-Mod0.0010.002
Dry Mouth-non-SAE-Mild00.002
Dry Skin-non-SAE-Mild00.002
Dysmenorrhoea-non-SAE-Mild0.0010
Dyspepsia-non-SAE-Mild00.005
Dysplastic Naevus-non-SAE-Mod0.0010
Dyspnoea-non-SAE-Mild0.0010.002
Dyspnoea-non-SAE-Mod0.0010
Dysuria-non-SAE-Mild0.0010.002
Dysuria-non-SAE-Mod0.0010
Ear Infection-non-SAE-Mild0.0010
Ear Infection-non-SAE-Mod0.0020
Ear Pain-non-SAE-Mild0.0010
Ear Pain-non-SAE-Mod0.0010
Ear Pruritus-non-SAE-Mild00.002
Ecchymosis-non-SAE-Mild0.0020
Ecchymosis-non-SAE-Mod00.002
Eczema-non-SAE-Mild00.003
Eczema-non-SAE-Mod0.0030
Empty Sella Syndrome-non-SAE-Mild0.0010
Epilepsy-non-SAE-Mod0.0010
Epistaxis-non-SAE-Mild0.0070.008
Erythema-non-SAE-Mild0.0010
Eschar-non-SAE-Mild0.0010
Excoriation-non-SAE-Mild0.0050.002
Excoriation-non-SAE-Mod0.0010
Eye Haemorrhage-non-SAE-Mild0.0010
Eye Infection-non-SAE-Mild0.0010.002
Eye Pain-non-SAE-Mild00.002
Eye Swelling-non-SAE-Mild0.0010
Eyelid Ptosis-non-SAE-Mild0.0010
Facial Bones Fracture-non-SAE-Mod00.002
Facial Pain-non-SAE-Mod0.0010
Fall-non-SAE-Mild0.0020.002
Fall-non-SAE-Sev00.002
Fatigue-non-SAE-Mild0.0130.025
Fatigue-non-SAE-Mod0.0040.013
Fatigue-non-SAE-Sev0.0010
Femur Fracture-SAE-Sev00.002
Fibromyalgia-non-SAE-Mod0.0010.002
Flatulence-non-SAE-Mod0.0010
Flushing-non-SAE-Mod00.002
Folliculitis-non-SAE-Mild0.0010
Food Poisoning-non-SAE-Mild0.0010
Food Poisoning-non-SAE-Mod0.0010
Foot Fracture-non-SAE-Mod0.0010
Free Haemoglobin Present-non-SAE-Mild0.0010
Free Haemoglobin Present-non-SAE-Mod0.0010
Frequent Bowel Movements-non-SAE-Mod0.0010
Fungal Infection-non-SAE-Mild0.0010.002
Fungal Skin Infection-non-SAE-Mild0.0010
SecondaryRate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).

Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per infusion
Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (G-M).
Number of AEs per infusionIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Gastric Stenosis-non-SAE-Mod0.0010
Gastritis-non-SAE-Mild0.0010
Gastroenteritis-non-SAE-Mild0.0020
Gastroenteritis-non-SAE-Mod0.0010
Gastroenteritis Salmonella-non-SAE-Mod0.0010
Gastroenteritis Viral-non-SAE-Mild0.0030.002
Gastroenteritis Viral-non-SAE-Mod0.0020.002
Gastrointestinal Viral Infection-non-SAE-Mild0.0010
Gastrooesophageal Reflux Disease-non-SAE-Mild0.0020
Gastrooesophageal Reflux Disease-non-SAE-Mod0.0010
Genital Herpes-non-SAE-Mild0.0010.003
Genital Herpes-non-SAE-Mod00.002
Gingival Erosion-non-SAE-Mild0.0010
Gingivitis-non-SAE-Mild0.0010
Glaucoma-non-SAE-Mod0.0010
Glycosuria-non-SAE-Mild0.0010
Gout-non-SAE-Mod0.0010
Haematochezia-non-SAE-Mild0.0010
Haematospermia-non-SAE-Mild0.0010
Haematuria-non-SAE-Mild0.0010.002
Haemoglobin Decreased-non-SAE-Mild00.002
Haemolysis-non-SAE-Mild0.0010
Haemorrhoids-non-SAE-Mild0.0010
Haemorrhoids-non-SAE-Mod0.0010
Hand Fracture-non-SAE-Mod0.0010
Headache-non-SAE-Mild0.0260.065
Headache-non-SAE-Mod0.0040.003
Heart Rate Irregular-non-SAE-Mild0.0010.002
Herpes Zoster-non-SAE-Mod0.0020
Hiatus Hernia-non-SAE-Mild0.0010
Hydrocele-non-SAE-Mild0.0010
Hypercapnia-non-SAE-Mild0.0010
Hypercholesterolaemia-non-SAE-Mild0.0010
Hypersensitivity-non-SAE-Mild0.0010
Hypertension-non-SAE-Mild0.0010.002
Hypertension-non-SAE-Mod0.0040
Hypertension-SAE-Mod0.0010
Hypoaesthesia-non-SAE-Mild0.0010
Hypokalaemia-non-SAE-Mild00.003
Hypothyroidism-non-SAE-Mild00.003
Hypothyroidism-non-SAE-Mod0.0010
Impetigo-non-SAE-Mild0.0010
Incision Site Pain-non-SAE-Mod0.0010
Increased Upper Airway Secretion-non-SAE-Mild0.0010
Inflammation Of Wound-non-SAE-Mild00.002
Influenza-non-SAE-Mod0.0040.007
Influenza Like Illness-non-SAE-Mild0.0020
Influenza Like Illness-non-SAE-Mod0.0010
Infusion Site Abscess-non-SAE-Mild0.0010
Infusion Site Bruising-non-SAE-Mild0.0010
Infusion Site Discolouration-non-SAE-Mild0.0010
Infusion Site Discomfort-non-SAE-Mild0.0050.003
Infusion Site Erythema-non-SAE-Mild0.0140
Infusion Site Erythema-non-SAE-Mod0.0010
Infusion Site Induration-non-SAE-Mild0.0010
Infusion Site Mass-non-SAE-Mild0.0010
Infusion Site Oedema-non-SAE-Mild0.0010
Infusion Site Pain-non-SAE-Mild0.0490.028
Infusion Site Pain-non-SAE-Mod0.0040.003
Infusion Site Pruritus-non-SAE-Mild0.0190
Infusion Site Swelling-non-SAE-Mild0.0020
Infusion Site Swelling-non-SAE-Sev0.0010
Injection Site Pain-non-SAE-Mild0.0020
Insomnia-non-SAE-Mild0.0030
Insomnia-non-SAE-Mod00.002
Intervertebral Disc Degeneration-non-SAE-Mild0.0010
Iron Deficiency Anaemia-non-SAE-Mild0.0010
Irritable Bowel Syndrome-non-SAE-Mod0.0010
Jejunal Stenosis-non-SAE-Mod0.0010
Joint Dislocation-non-SAE-Sev0.0010
Joint Injury-non-SAE-Mild0.0010
Joint Swelling-non-SAE-Mod00.002
Laceration-non-SAE-Mild00.002
Ligament Sprain-non-SAE-Mild0.0010
Ligament Sprain-non-SAE-Mod0.0010.003
Limb Discomfort-non-SAE-Mild00.002
Liver Function Test Abnormal-non-SAE-Mild0.0010
Local Swelling-non-SAE-Mild0.0020
Localised Infection-non-SAE-Mod0.0010
Loss Of Consciousness-non-SAE-Mild00.002
Lyme Disease-non-SAE-Mild0.0010
Lymph Gland Infection-non-SAE-Mod0.0010
Lymphadenitis-non-SAE-Mod00.002
Lymphadenitis Bacterial-non-SAE-Mild0.0010
Lymphadenopathy-non-SAE-Mild0.0030.003
Lymphopenia-non-SAE-Mild0.0010
Malaise-non-SAE-Mild0.0020.002
Medical Device Pain-non-SAE-Mild0.0010
Memory Impairment-non-SAE-Mild0.0010
Meniscus Injury-non-SAE-Mild0.0010
Menstrual Disorder-non-SAE-Mod0.0010
Mental Status Changes-SAE-Sev0.0010
Micturition Urgency-non-SAE-Mild00.002
Middle Ear Effusion-non-SAE-Mild00.002
Migraine-non-SAE-Mild0.0030.003
Migraine-non-SAE-Mod0.0030.008
Migraine-non-SAE-Sev00.002
Mitral Valve Incompetence-non-SAE-Mild0.0010
Molluscum Contagiosum-non-SAE-Mild0.0010.002
Mouth Ulceration-non-SAE-Mild00.002
Mucosal Inflammation-non-SAE-Mild0.0010
Muscle Contractions Involuntary-non-SAE-Mild0.0010
Muscle Spasms-non-SAE-Mild0.0030
Muscle Strain-non-SAE-Mild0.0010
Muscular Weakness-non-SAE-Mild00.002
Muscular Weakness-non-SAE-Mod0.0010
Musculoskeletal Pain-non-SAE-Mild0.0030
Musculoskeletal Pain-non-SAE-Mod0.0010.002
Myalgia-non-SAE-Mild0.0160.010
Myalgia-non-SAE-Mod0.0020.003
SecondaryRate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).

Categories presented as Preferred term-Seriousness-Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Severity: Mild; Mod (Moderate); Sev (Severe)

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per infusion
Rate of All AEs Per Infusion Categorized by MedDRA Preferred Terms, Seriousness and Severity (N-Z).
Number of AEs per infusionIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Nasal Congestion-non-SAE-Mild0.0070.008
Nasal Congestion-non-SAE-Mod0.0010
Nasal Discomfort-non-SAE-Mild0.0010
Nasopharyngitis-non-SAE-Mild0.0040.008
Nasopharyngitis-non-SAE-Mod0.0010
Nausea-non-SAE-Mild0.0240.028
Nausea-non-SAE-Mod0.0040.013
Nephrolithiasis-non-SAE-Mild00.002
Nerve Compression-non-SAE-Mild00.002
Neutrophil Count Decreased-non-SAE-Mild00.002
Ocular Hyperaemia-non-SAE-Mild00.002
Oedema Peripheral-non-SAE-Mild0.0030.008
Oedema Peripheral-non-SAE-Mod0.0030.002
Oral Candidiasis-non-SAE-Mild0.0010
Oral Herpes-non-SAE-Mild0.0040.003
Oral Pain-non-SAE-Mild00.002
Oral Pain-non-SAE-Mod00.002
Orchitis-non-SAE-Mod0.0010
Oropharyngeal Pain-non-SAE-Mild0.0030.002
Osteoarthritis-non-SAE-Mild0.0010.002
Osteoarthritis-non-SAE-Mod0.0010
Osteopenia-non-SAE-Mild0.0010
Osteoporosis-non-SAE-Mild00.002
Otitis Externa-non-SAE-Mild0.0010.002
Otitis Externa-non-SAE-Mod00.002
Otitis Media-non-SAE-Mod0.0010.002
Pain-non-SAE-Mild0.0060
Pain In Extremity-non-SAE-Mild0.0030.002
Pain In Extremity-non-SAE-Sev00.002
Palpitations-non-SAE-Mild0.0010
Panic Attack-non-SAE-Mild00.002
Papule-non-SAE-Mild0.0010
Paraesthesia-non-SAE-Mild0.0010
Paranasal Cyst-non-SAE-Mild0.0010
Pelvic Pain-non-SAE-Mod0.0010
Pericardial Effusion-non-SAE-Mild0.0010
Perineurial Cyst-non-SAE-Mod0.0010
Periodontal Disease-non-SAE-Mild0.0010
Pharyngitis-non-SAE-Mild0.0040.002
Pharyngitis-non-SAE-Mod00.002
Pharyngitis Streptococcal-non-SAE-Mild0.0010
Pleural Effusion-non-SAE-Mild0.0010
Pleural Effusion-non-SAE-Mod0.0010
Pneumonia-non-SAE-Mild0.0010
Pneumonia Bacterial-non-SAE-Mod0.0010
Pneumonia Pseudomonas Aeruginosa-SAE-Sev0.0010
Pollakiuria-non-SAE-Mild00.002
Pollakiuria-non-SAE-Mod0.0010
Polycystic Ovaries-non-SAE-Mild00.002
Post Procedural Complication-non-SAE-Mod0.0010
Post Procedural Haemorrhage-non-SAE-Mild0.0010
Post Procedural Swelling-non-SAE-Mild0.0010
Procedural Nausea-non-SAE-Mod0.0010
Procedural Pain-non-SAE-Mild00.002
Procedural Pain-non-SAE-Mod0.0060.002
Proctalgia-non-SAE-Mod0.0010
Productive Cough-non-SAE-Mild0.0010
Protein Urine Present-non-SAE-Mild0.0010
Pruritus-non-SAE-Mild0.0020.010
Pruritus-non-SAE-Mod0.0010
Pruritus Allergic-non-SAE-Mod00.002
Pruritus Generalised-non-SAE-Mild00.002
Pulmonary Hypertension-non-SAE-Mild0.0010
Pulmonary Hypertension-non-SAE-Mod0.0010
Pulmonary Vascular Disorder-non-SAE-Mod0.0010
Puncture Site Pain-non-SAE-Mild00.002
Puncture Site Pain-non-SAE-Mod00.003
Purpura Senile-non-SAE-Mild00.002
Pyogenic Granuloma-non-SAE-Mod0.0010.002
Pyrexia-non-SAE-Mild0.0090.008
Pyrexia-non-SAE-Mod0.0010
Pyuria-non-SAE-Mild00.002
Rales-non-SAE-Mod0.0010.002
Rash-non-SAE-Mild0.0010.002
Rash Generalised-non-SAE-Mild00.002
Rectal Polyp-non-SAE-Mod0.0010
Red Blood Cells Urine Positive-non-SAE-Mild0.0010
Respiratory Tract Congestion-non-SAE-Mild0.0010
Respiratory Tract Congestion-non-SAE-Mod0.0010
Respiratory Tract Infection-non-SAE-Mild0.0010
Respiratory Tract Infection-non-SAE-Mod0.0010
Restless Legs Syndrome-non-SAE-Mild0.0010
Rhinitis-non-SAE-Mild0.0010
Rhinitis Perennial-non-SAE-Mild0.0010
Rhinorrhoea-non-SAE-Mild0.0010.003
Right Atrial Dilatation-non-SAE-Mild0.0010
Rotator Cuff Syndrome-non-SAE-Mild0.0010
Scab-non-SAE-Mild0.0010
Scar-non-SAE-Mild0.0010
Scoliosis-non-SAE-Mild00.002
Scratch-non-SAE-Mild0.0010
Scrotal Swelling-non-SAE-Mild0.0020
Seborrhoeic Keratosis-non-SAE-Mod0.0010
Sinus Congestion-non-SAE-Mild0.0010.002
Sinus Headache-non-SAE-Mild0.0010
Sinusitis-non-SAE-Mild0.0210.005
Sinusitis-non-SAE-Mod0.0180.022
Skin Hyperpigmentation-non-SAE-Mild0.0010
Skin Lesion-non-SAE-Mild0.0010
Skin Mass-non-SAE-Mild0.0010.002
Sleep Apnoea Syndrome-non-SAE-Mild0.0010
Slow Speech-non-SAE-Mod0.0010
Solar Lentigo-non-SAE-Mild0.0010
Somnolence-non-SAE-Mild0.0010
Speech Disorder-non-SAE-Mild00.002
Spermatocele-non-SAE-Mild0.0010
Spinal Compression Fracture-non-SAE-Mod0.0010
Spinal Meningeal Cyst-SAE-Sev0.0010
Spinal Osteoarthritis-non-SAE-Mild0.0020
Squamous Cell Carcinoma-non-SAE-Mod0.0030.003
Stress-non-SAE-Mod0.0010
Suicide Attempt-non-SAE-Sev0.0010
Sunburn-non-SAE-Mild0.0010
Swelling Face-non-SAE-Mod0.0010
Swelling Face-non-SAE-Sev00.002
Swollen Tongue-non-SAE-Mild0.0010
Synovial Cyst-non-SAE-Mild0.0010
Tachycardia-non-SAE-Mild0.0030.002
Tachycardia-non-SAE-Mod0.0010
Tendon Disorder-non-SAE-Sev0.0010
Tendonitis-non-SAE-Mild0.0010
Tendonitis-non-SAE-Mod0.0010
Testicular Microlithiasis-non-SAE-Mild0.0010
Testicular Pain-non-SAE-Mod0.0010
Thermal Burn-non-SAE-Mild00.002
Thinking Abnormal-non-SAE-Mod0.0010
Thrombocytopenia-non-SAE-Mild0.0010
Tibia Fracture-non-SAE-Sev0.0010
Tinea Cruris-non-SAE-Mild0.0010
Tinea Infection-non-SAE-Mild0.0010
Tooth Abscess-non-SAE-Mild00.002
Tooth Abscess-non-SAE-Mod00.002
Tooth Fracture-non-SAE-Mod0.0010
Tooth Infection-non-SAE-Mild0.0010
Tooth Infection-non-SAE-Mod0.0010
Toothache-non-SAE-Mod00.002
Toxicity To Various Agents-SAE-Sev0.0010
Tracheal Stenosis-non-SAE-Mild00.002
Transient Ischaemic Attack-SAE-Mod00.002
Traumatic Haematoma-non-SAE-Mild0.0010
Tricuspid Valve Incompetence-non-SAE-Mild0.0010
Trigeminal Neuralgia-non-SAE-Mild0.0010
Tympanic Membrane Scarring-non-SAE-Mild0.0010
Type 2 Diabetes Mellitus-non-SAE-Mod0.0010
Upper Limb Fracture-non-SAE-Mod0.0010
Upper Limb Fracture-non-SAE-Sev0.0010
Upper Respiratory Tract Infection-non-SAE-Mild0.0100.013
Upper Respiratory Tract Infection-non-SAE-Mod0.0080.003
Upper-Airway Cough Syndrome-non-SAE-Mild0.0010.002
Urethritis-non-SAE-Mild0.0010
Urinary Tract Infection-non-SAE-Mild0.0030.007
Urinary Tract Infection-non-SAE-Mod0.0040.003
Urticaria-non-SAE-Mild00.003
Uterine Polyp-non-SAE-Mod0.0010
Vaginal Prolapse-SAE-Mod0.0010
Vaginitis Bacterial-non-SAE-Mild0.0010
Varicose Vein-non-SAE-Mild0.0010
Vasomotor Rhinitis-non-SAE-Mild0.0010
Vein Pain-non-SAE-Mild00.002
Ventricular Hypokinesia-non-SAE-Mild0.0010
Vessel Puncture Site Bruise-non-SAE-Mild0.0010
Viral Infection-non-SAE-Mild0.0020
Viral Infection-non-SAE-Mod00.002
Viral Pharyngitis-non-SAE-Mild0.0010
Viral Pharyngitis-non-SAE-Mod00.002
Viral Rash-non-SAE-Mod0.0010
Viral Upper Respiratory Tract Inf.-non-SAE-Mild0.0180.008
Viral Upper Respiratory Tract Inf-non-SAE-Mod0.0010.002
Vision Blurred-non-SAE-Mild0.0010
Vitamin B12 Deficiency-non-SAE-Mild0.0010
Vitamin D Decreased-non-SAE-Mild00.002
Vitamin D Deficiency-non-SAE-Mild0.0010
Vitamin D Deficiency-non-SAE-Mod0.0010
Vomiting-non-SAE-Mild0.0080.003
Vomiting-non-SAE-Mod0.0030.003
Vulvar Dysplasia-non-SAE-Mild0.0010
Vulvovaginal Candidiasis-non-SAE-Mild0.0010
Vulvovaginal Mycotic Infection-non-SAE-Mild0.0030.002
Vulvovaginal Mycotic Infection-non-SAE-Mod0.0010
Wheezing-non-SAE-Mod0.0010
Wisdom Teeth Removal-non-SAE-Mild0.0010
Wisdom Teeth Removal-non-SAE-Sev0.0010
Wound-non-SAE-Mild00.002
Wrist Fracture-non-SAE-Mod00.002
Xeroderma-non-SAE-Mild0.0010
SecondaryRate of AEs Per Participant (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")

Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per participant
Rate of AEs Per Participant (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")
Number of AEs per participantIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Total AEs, Mild4.6352.137
Total AEs, Moderate0.4760.392
Total AEs, Severe0.0160.059
Total AEs, Total5.1272.588
Local nsAEs, Mild2.4760.373
Local AEs, Moderate0.1110
Local AEs, Severe0.0160
Local AEs, Total2.6030.373
Systemic AEs including infections, Mild2.1591.765
Systemic AEs including infections, Moderate0.3650.392
Systemic AEs including infections, Severe00.059
Systemic AEs including infections, Total2.5242.216
Systemic AEs excluding infections, Mild2.1591.765
Systemic AEs excluding infections, Moderate0.3650.392
Systemic AEs excluding infections, Severe00.059
Systemic AEs excluding infections, Total2.5242.216
SecondaryRate of AEs Per Infusion (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")

Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per infusion
Rate of AEs Per Infusion (Including and Excluding Infections) Determined by the Investigator to be Related to the Study Drug That Occur at Any Time During the Study ("Related")
Number of AEs per infusionIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Total AEs, Mild0.1830.182
Total AEs, Moderate0.0190.033
Total AEs, Severe0.0010.005
Total AEs, Total0.2020.221
Local AEs, Mild0.0980.032
Local AEs, Moderate0.0040
Local AEs, Severe0.0010
Local AEs, Total0.1030.032
Systemic AEs including infections, Mild0.0850.151
Systemic AEs including infections, Moderate0.0140.033
Systemic AEs including infections, Severe00.005
Systemic AEs including infections, Total0.0990.189
Systemic AEs excluding infections, Mild0.0850.151
Systemic AEs excluding infections, Moderate0.0140.033
Systemic AEs excluding infections, Severe00.005
Systemic AEs excluding infections, Total0.0990.189
SecondaryRate of AEs Per Participant (Including and Excluding Infections) Temporarily Associated With the Infusion

Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (nsAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per participant
Rate of AEs Per Participant (Including and Excluding Infections) Temporarily Associated With the Infusion
Number of AEs per participantIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Total, nsAE, Mild5.9212.275
Total, nsAE, Moderate1.1110.647
Total, nsAE, Severe0.0320.059
Total nsAE, Total7.0632.980
Total, SAE, Moderate0.0160
Total, SAE, Severe0.0160
Total, SAE, Total0.0320
Local, nsAE, Mild2.4920.353
Local, nsAE, Moderate0.1110.039
Local, nsAE, Severe0.0160
Local, nsAE, Total2.6190.392
Systemic including infections, nsAE, Mild3.4291.922
Systemic including infections, nsAE, Moderate1.0000.608
Systemic including infections, nsAE, Severe0.0160.059
Systemic including infections, nsAE, Total4.4442.588
Systemic including infections, SAE, Moderate0.0160
Systemic including infections, SAE, Severe0.0160
Systemic including infections, SAE, Total0.0320
Systemic excluding infections, nsAE, Mild3.1111.922
Systemic excluding infections, nsAE, Moderate0.8730.608
Systemic excluding infections, nsAE, Severe0.0160.059
Systemic excluding infections, nsAE, Total4.0002.588
Systemic excluding infections, SAE, Moderate0.0160
Systemic excluding infections, SAE, Severe0.0160
Systemic excluding infections, SAE, Total0.0320
SecondaryRate of AEs Per Infusion (Including and Excluding Infections) Temporarily Associated With the Infusion

Categories presented as adverse event (AE) type : Total, Local, Systemic including infections, Systemic excluding infections, Seriousness: Serious AE (SAE), non-serious AE (non-SAE) and Severity (Mild, Moderate, Severe, Total). All of these adverse events are non-serious AEs.

Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Number of AEs per infusion
Rate of AEs Per Infusion (Including and Excluding Infections) Temporarily Associated With the Infusion
Number of AEs per infusionIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Total, non-SAE, Mild0.2330.194
Total, non-SAE, Moderate0.0440.055
Total, non-SAE, Severe0.0010.005
Total non-SAE, Total0.2780.254
Total, SAE, Moderate0.0010
Total, SAE, Severe0.0010
Total, SAE, Total0.0010
Local, non-SAE, Mild0.0980.030
Local, non-SAE, Moderate0.0040.003
Local, non-SAE, Severe0.0010
Local, non-SAE, Total0.1030.033
Systemic including infections, non-SAE, Mild0.1350.164
Systemic including infections, non-SAE, Moderate0.0390.052
Systemic including infections, non-SAE, Severe0.0010.005
Systemic including infections, non-SAE, Total0.1750.221
Systemic including infections, SAE, Moderate0.0010
Systemic including infections, SAE, Severe0.0010
Systemic including infections, SAE, Total0.0010
Systemic excluding infections, non-SAE, Mild0.1230.156
Systemic excluding infections, non-SAE, Moderate0.0340.043
Systemic excluding infections, non-SAE, Severe0.0010.005
Systemic excluding infections, non-SAE, Total0.1580.204
Systemic excluding infections, SAE, Moderate0.0010
Systemic excluding infections, SAE, Severe0.0010
Systemic excluding infections, SAE, Total0.0010
SecondaryPercentage of Infusions Associated With One or More Local AEs (Including and Excluding Infections), at Any Time During the Study
Time frame:
Throughout entire study period (up to 3 years). Duration of participation for each participant is variable depending on date of enrollment and their anti-rHuPH20 binding antibody titer.
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With One or More Local AEs (Including and Excluding Infections), at Any Time During the Study
Percentage of infusionsIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
Including Infections8.83.7
Excluding Infections8.73.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGSC, 10% - rHuPH20—9/63 (14.3%)60/63 (95.2%)
Safety Follow-up - IGSC, 10% or IGIV, 10% Only—3/51 (5.9%)45/51 (88.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
CellulitisInfections and infestations0/631/51
Femur FractureInjury, poisoning and procedural complications0/631/51
Transient Ischaemic AttackNervous system disorders0/631/51
Aortic Valve IncompetenceCardiac disorders1/630/51
Atrial FibrillationCardiac disorders1/630/51
Cardiac Failure CongestiveCardiac disorders1/630/51
AppendicitisInfections and infestations1/630/51
Cryptosporidiosis InfectionInfections and infestations1/630/51
Pneumonia Pseudomonas AeruginosaInfections and infestations1/630/51
Toxicity to Various AgentsInjury, poisoning and procedural complications1/630/51
Most frequent other events
Showing 10 of 54
Most frequent other events
EventIGSC, 10% - rHuPH20Safety Follow-up - IGSC, 10% or IGIV, 10% Only
SinusitisInfections and infestations25/6311/51
HeadacheNervous system disorders24/6310/51
Upper Respiratory Tract InfectionInfections and infestations18/639/51
NauseaGastrointestinal disorders16/634/51
Infusion site PainGeneral disorders16/632/51
Viral Upper Respiratory Tract InfectionInfections and infestations16/633/51
BronchitisInfections and infestations14/636/51
DiarrhoeaGastrointestinal disorders13/633/51
VomitingGastrointestinal disorders13/632/51
AsthmaRespiratory, thoracic and mediastinal disorders13/636/51

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(Years)Participants Aged 2 to <12 YearsParticipants Aged 12 to <16 YearsParticipants Aged 16 to <65 YearsParticipants Aged 65 Years and OlderTotal
Median10.5 (9 to 11)15.0 (13 to 15)47.0 (16 to 64)71.0 (65 to 80)43.0 (9 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Participants Aged 2 to <12 YearsParticipants Aged 12 to <16 YearsParticipants Aged 16 to <65 YearsParticipants Aged 65 Years and OlderTotal
Female1123732
Male3624134
Region of Enrollment
Region of Enrollment(Participants)Participants Aged 2 to <12 YearsParticipants Aged 12 to <16 YearsParticipants Aged 16 to <65 YearsParticipants Aged 65 Years and OlderTotal
United States4747866
08

Study locations

11 sites
  • Cypress, California, United States
  • Irvine, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Centennial, Colorado, United States
  • North Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Hinsdale, Illinois, United States
  • Bronx, New York, United States
  • Dallas, Texas, United States
  • Galveston, Texas, United States
09

References and documents

Publications

  • Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. J Clin Immunol. 2016 Aug;36(6):571-82. doi: 10.1007/s10875-016-0298-x. Epub 2016 May 25. PubMed 27220317 ↗
  • Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, Yel L. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy. 2022 Mar;14(4):215-224. doi: 10.2217/imt-2021-0256. Epub 2021 Dec 21. PubMed 34931880 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Aug 2013, 36 months.

Results were first posted in May 2016, 2 years 9 months after primary completion. A results delay was requested in Sep 2014.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2010
First posted
Aug 4, 2010
StartActual
Jul 28, 2010
Primary completionActual
Aug 6, 2013
CompletionActual
Aug 6, 2013
Results delay requested
Sep 8, 2014
Results first posted
May 26, 2016
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01175213
Responsible party
Sponsor
First posted
Aug 4, 2010
Start date
Jul 28, 2010
Primary completion
Aug 6, 2013
Completion
Aug 6, 2013
Results posted
May 26, 2016
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion